

**SACHS**  
**ASSOCIATES**

**5<sup>TH</sup> ANNUAL**  
**IMMUNO-ONCOLOGY**  
**BD&L AND INVESTMENT**  
**FORUM**

31<sup>ST</sup> MAY 2019 | WALDORF ASTORIA CHICAGO HOTEL | UNITED STATES

**CONFERENCE GUIDE**

[www.sachsforum.com](http://www.sachsforum.com)

Please do not take the hard copy –  
scan QR below to download:



**SACHS ASSOCIATES ARE DELIGHTED TO WELCOME YOU TO THE:**

## **5<sup>TH</sup> ANNUAL IMMUNO-ONCOLOGY BD&L & INVESTMENT FORUM**

**31<sup>ST</sup> MAY 2019  
WALDORF ASTORIA CHICAGO HOTEL  
USA**

Taking place on the first day of ASCO, the 5<sup>th</sup> Annual Immuno-Oncology BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering, funding and investment. We expect over 250 delegates and around 25+ presentations by listed and private biotechnology companies seeking licensing & investment.

Numerous networking opportunities available via an online One-2-One meeting system with dedicated meeting facilities to make the event more transactional.

### **GENERAL INFORMATION**

The registration desk will be open from 7.20am on May 31<sup>st</sup>, although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session.

Networking at the summit is facilitated by our online One-2-One meeting system, which is available to all participants. The One-2-One meetings are being held in Hemingway Room. Please bring with you a copy of your diary. Should you have any queries about your schedule, the Sachs team situated by the meeting tables is available for your assistance.

Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk.

There will be networking lunch, reception, and coffee stations set up in the rooms throughout the event.

### **REQUEST FOR PRESENTATIONS**

Please use the agenda to mark off presentations that you are interested in and email your request to [Silvia@sachsforum.com](mailto:Silvia@sachsforum.com) after the conference. We will endeavor to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter.

Please note that we DO NOT have copies of the slides that are shown during the conference.

Silver sponsor:



**BeiGene**

Supported by:



|Citigate Dewe Rogerson



**EDISON**

**FREE MIND**  
Non-Dilutive Funding Experts

**INSTINCTIF**  
PARTNERS



Plattform  
**Life Sciences**





## **EVENTS DIARY**

For the regular updates, sponsorship, presenting and attending opportunities and further information regarding any of our future events, please contact Silvia Kar on [Silvia@sachsforum.com](mailto:Silvia@sachsforum.com).

### **7<sup>TH</sup> ANNUAL HEALTHTECH INVESTMENT FORUM**

24<sup>TH</sup> SEPTEMBER 2019 • CONGRESS CENTER BASEL • SWITZERLAND

Now in its seventh year we will be hosting the 7<sup>th</sup> Annual HealthTech Investment Forum on September 24<sup>th</sup>, 2019. The forum covers innovation in the digital health and medtech and devices sectors. The programme features topical keynotes and panels with industry leaders and features over 20 corporate presentations by public and growth companies. In addition, there is a rising stars session with over 20 start-ups presenting.

We expect over 250 delegates drawn from Digital Health, AI, MedTech/Device companies, bankers, investors and advisors.

### **19<sup>TH</sup> ANNUAL BIOTECH IN EUROPE FORUM**

25<sup>TH</sup> - 26<sup>TH</sup> SEPTEMBER 2019 • CONGRESS CENTER BASEL • SWITZERLAND

The 19<sup>th</sup> Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. This highly transactional event draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. Supported and designed by leading figures within Europe's pharmaceutical and biotech industry, this event will once again be covered by our regular media partners. We expect over 700 delegates and over 100 presenting companies, and 30+ pitches by seed companies.

The #Sachs\_BE19 forum will be held for the sixth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature a number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas. We expect more than 2000 meetings to take place throughout the 2 days.

### **3<sup>RD</sup> ANNUAL NEUROSCIENCE INNOVATION FORUM**

12<sup>TH</sup> JANUARY 2020 • MARINES' MEMORIAL CLUB • SAN FRANCISCO • USA

Building on the success of our 2<sup>nd</sup> Annual NIF we are pleased to announce our 3<sup>rd</sup> Annual Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology to take place at the Marines' Memorial Club, San Francisco on the 12<sup>th</sup> of January 2020, a day before the JP Morgan meeting.

The programme will cover BioPartnering for CNS, with industry keynotes and panels on AD, PD, Neuropsychiatry and Pain Management. Moreover, there are panels on innovation in NeuroTech covering banking, device, diagnostics and software. The target audience are buy and sell side analysts from investment banks and funds and partnering executives from pharma, biotech and medtech companies. We anticipate over 200 delegates and 30+ company presentations by established listed, private and emerging companies.

### **13<sup>TH</sup> ANNUAL EUROPEAN LIFE SCIENCES CEO FORUM**

19<sup>TH</sup> - 20<sup>TH</sup> FEBRUARY 2020 • HILTON ZURICH AIRPORT HOTEL • SWITZERLAND

Back for its 13<sup>th</sup> Annual edition, this global bio-pharma industry forum addresses through its conference programme the main challenges for 2020 in investment, partnering and alliance management. Key players contribute their insights in panels which cover the macro picture as well as innovation in different therapeutic sectors. The forum also features keynote speeches by KOL and about 60 selected corporate presentations from established (public and private) and emerging biotechs seeking to promote investment and partnering opportunities. We expect over 350 delegates to attend the event.

## **ONLINE ONE-2-ONE MEETING SYSTEM AVAILABLE AT ALL SACHS EVENTS**

In order to offer the best possible provision for networking opportunities and dealmaking Sachs Associates provides delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

**KEYNOTE SPEAKER****Real Endpoints LLC****Roger Longman**

Co-Founder &amp; Chairman

Roger Longman is co-founder and chairman of Real Endpoints LLC, a leading reimbursement-focused analytics and advisory firm.

Roger is recognized as an expert in biopharmaceutical strategy and reimbursement and often speaks at key industry events organized by important trade organizations, investment banks, venture capital firms, and leading biopharma companies.

He has been involved with the health-care industry for more than 30 years. At his first venture, Windhover Information, he and his team created a number of industry-standard analytical sources, including must-read strategy publications such as IN VIVO and Start-Up, the strategic transactions database and a major conference business for senior executives. The business was acquired by Elsevier where for two years Longman ran the company's pharmaceutical business information group.

Roger co-founded Real Endpoints in 2011. Since then, it has developed a number of value-based approaches to developing and commercializing drugs and diagnostics - including proprietary tools for objective analysis of drug value; innovative contracting structures and processes for negotiating, monitoring, and reconciling the agreements; and objective assessments of, and development of strategies for, patient support services.

He lectures regularly at several leading universities and co-directed the Wharton-Windhover pharmaceutical program at The Wharton School. Mr. Longman completed his BA at Cornell University and MA at the University of North Carolina at Chapel Hill, then taught for three years at the European division of the University of Maryland.

**SPEAKERS****OSE Immunotherapeutics****Alexis Peyroles**

CEO

Since 2013, he has been involved in the company as Chief Financial Officer, in charge of Business Development and from May 2016 to April 2018, he served as Chief Operating Officer, in charge of Finance, Business Development and Operations.

Alexis Peyroles has more than 20 years of international management and financial control experience, having served in multiple related positions. He joined Sanofi-Aventis in 1996 as Financial Controller in Japan before becoming Head of Financial Control for the Baltic States. He was subsequently named Head of activities for Business Development in Eastern Europe. In 2005, Alexis joined the Guerbet group (a leader in the field of contrast products, especially in medical imaging) as Financial Control Manager and in 2009 became Chief Executive Officer for Latin America, based in Brazil.

Alexis Peyroles graduated from EDHEC Business School and holds an Executive MBA from Imperial College in London.

**GlaxoSmithKline****Axel Hoos**

SVP, Therapeutic Area Head of Oncology R&amp;D

Dr. Axel Hoos is Senior Vice President, R&D Governance Chair, and Therapeutic Area (TA) Head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). He is responsible for discovery and development in Oncology with focus on immuno-oncology, epigenetics, cell therapies and genetic medicine. As R&D governance chair he oversees technical and funding review committees.

He returned GSK to Oncology after the divestment of its marketed medicines to Novartis in 2015 and is responsible for GSK's Oncology portfolio focusing on innovative medicines to deliver transformational benefit to patients. Recent portfolio expansion included the acquisition of Tesaro, a co-development partnership with Merck-Serono, and the in-licensing of the first cell therapy active in solid tumors from Adaptimmune.

Dr. Hoos also serves as Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Director on the Board of Imugene, a biotech company, Co-Director of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI).

His efforts focus on novel therapies for life-threatening diseases, scientific and technical innovation, and business and scientific collaboration. Through his leadership a paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology (Nat. Rev. Drug Discovery 2016, 15(4);, 235-47).


Previously, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy and the first checkpoint inhibitor drug in Immuno-Oncology. The discovery of ipilimumab's scientific mechanism was honored with the Nobel prize for Physiology or Medicine to Dr. James Allison in 2018. Before BMS, Dr. Hoos was Senior Director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.

Dr. Hoos holds an MD from Ruprecht-Karls-University and a PhD in molecular oncology from the German Cancer Research Center (DKFZ) both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.

**New Enterprise Associates (NEA)****Bibhash Mukhopadhyay**

Principal

Bibhash is a Principal at New Enterprise Associates (NEA), where he focuses on investing in emerging therapeutics and device companies, assisting them grow and create value. Previously, he was at AstraZeneca / MedImmune as an Associate Director of Business Development, where his responsibilities spanned end-to-end in the deal-making spectrum, from search and evaluation to transactions, with focus on the immune-oncology and immunology spaces. He started his career at Johnson and Johnson, where he held multiple Business Development roles, at different times, in Global Surgery, Oncology and Emerging Technologies. Bibhash's doctoral research work focused on pathophysiology of retinal diseases using tools of cell biology and mathematical modeling, during which he also consulted for venture funds and start-ups.

**Jefferies Group LLC****Biren Amin**

Managing Director

Biren Amin joined Jefferies in 2011 and is a Managing Director and Senior Research Analyst covering the U.S. biotechnology sector. Mr. Amin has over 12 years sell side experience as an equity research analyst which began at Prudential Securities. Prior to that he worked for five years at Aventis Pharmaceuticals (now Sanofi). He holds a B.S. in Pharmacy from University of Sciences at Philadelphia. He also holds an M.S. in Pharmacy from Arnold and Marie Schwartz College of Pharmacy, and an M.B.A. from New York University.

**Cowen, Inc.****Boris Peaker**

Managing Director, Biotechnology Equity Research

Boris Peaker is a managing director and senior research analyst covering emerging growth biotechnology companies. Prior to rejoining Cowen in 2014, Dr. Peaker was a senior analyst at Oppenheimer & Co. and Rodman & Renshaw, covering large-, mid-, and small-cap biotechnology stocks. Dr. Peaker holds a BS in physics and chemistry from Stony Brook University and a Ph.D. in biophysics from Stanford University. He is a CFA charterholder.

**Loncar Investment LLC****Brad Loncar**

CEO

Brad Loncar is an independent biotechnology investor and CEO of Loncar Investments, a firm that specializes in the creation of thematic biotechnology investment indexes. Its first two products are The Cancer Immunotherapy Index and The China BioPharma Index. Mr. Loncar previously worked in the financial services industry at Franklin Templeton Investments, where he was a member of the Management Training Program, and was appointed to serve in a Senior Advisor role at the U.S. Department of the Treasury. He currently writes biotechnology commentary at [www.LoncarBlog.com](http://www.LoncarBlog.com) and has contributed opinion pieces to Endpoints News and Xconomy. He is one of the most followed commentators in biotech on social media. With a focus on oncology, Loncar Investments is an official charitable partner of the Cancer Research Institute.

**Immunicum AB****Carlos de Sousa**

CEO

Carlos de Sousa is a medical doctor by training, having earned his degree at School of Medicine University of Lisbon and holds an Executive MBA from the Stern School of Business New York University. He has more than 25 years of senior level experience in the global pharmaceutical and biotech industry including business development, mergers & acquisitions, global marketing and clinical development. Prior to joining Immunicum he held senior positions at Nycomed/Takeda, Pfizer, Novartis, Newron Pharmaceuticals and Zealand Pharma among others.



**Vertex Ventures HC****Carolyn Ng**


Managing Director

Carolyn Ng is Managing Director at Vertex Ventures HC. At Vertex, Carolyn is responsible for driving venture investments across biotechnology, medical devices and health technology fields. Carolyn currently serves on the Board of Directors for Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Bicycle Therapeutics and Nuvaira. She is also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for USD430M) and Earlens. She has previously closely supported Vertex's investment into Twelve (acquired by Medtronic for USD458M). Working across the US, Europe and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development and syndication.

She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients' lives. Prior to joining Vertex, Carolyn was also a Pharma Strategy Consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm where she led global strategic projects for clientele comprised of the top 20 global pharmaceutical companies.

Carolyn holds a PhD in Cancer Molecular Biology from the NUS Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS PhD Scholarship. As an inventor and patent holder of a novel small molecule nuclear receptor activator indicated for the treatment of neuroblastoma, her research work was awarded the AAPS-NUS Prize (American Association of Pharmaceutical Society-National University of Singapore). She also holds a BS degree in Pharmacy with First Class Honours from the National University of Singapore, where she received the PSS Prize for Pharmaceuticals awarded to the top graduating student in the class.

Outside of Vertex, Carolyn is a retired competitive squash player, a high intensity interval training enthusiast, and an aspiring but untalented oil painter.

**Amgen, Inc.****Chris DeRespino**

Executive Director, Business Development

Chris is a co-leader of the business development transactions capability at Amgen, with a particular focus on the oncology therapeutic area. Chris joined Amgen as part of the Onyx acquisition in October 2013 and is based in San Francisco. Since joining Amgen, he has led a range of transactions including Amgen's immuno-oncology collaborations with Molecular Partners, CytomX and Kite Pharma. While at Onyx, Chris served as a co-leader of the team responsible for Onyx's business development strategy and execution and supported Onyx's sale process. Prior to joining Onyx, Chris was a director in Pfizer's business development team in New York where supported deals across a broad spectrum of therapeutic areas and geographies. Earlier in his career, Chris worked as a senior consultant in CSC's healthcare practice.

Chris earned his MBA from NYU's Stern School of Business, and his BSE in Biomedical Engineering from The Johns Hopkins University.

**AstraZeneca**  
**Chris Sheldon**

Head of Oncology Search & Evaluation

Chris has worked in the UK at AstraZeneca (AZ) for over 16 years and is currently Head of Oncology Search & Evaluation in AZ's Strategy team in its Oncology Business Unit (OBU). Chris and his team are responsible for scouting of new oncology technologies and leading the technical evaluation of such new M&A, in-licensing, out-licensing (divestment) and collaboration opportunities in clinical stage oncology. Most recently, he led the evaluation of AstraZeneca's major \$6.9bn co-development/co-promotion deal with Daiichi-Sankyo for trastuzumab deruxtecan (DS-8201) an antibody drug conjugate. Previously Chris led both AZ's majority \$4 billion stake investment in Acerta Pharma for acalabrutinib, a potential best-in-class BTK inhibitor in haematology and a \$1.275bn immuno oncology collaboration deal with innate Pharma for monalizumab a novel NKG2A inhibitor. Chris has also evaluated and executed over a dozen novel combination collaboration deals for AstraZeneca's immune checkpoint inhibitor Imfinzi (durvalumab), best-in-class EGFR inhibitor Tagrisso (osimertinib) and first-in-class SERD Faslodex (fulvestrant).

Prior to this Chris worked in early stage oncology business development and was involved in all aspects of evaluation, due diligence and negotiation of deals. Before his business development career, Chris worked in discover research at AstraZeneca as a senior research chemist. He also holds a Ph.D. in chemistry from the University of Bristol, UK and a first class honours degree from the University of Sheffield, UK.

**BeiGene Ltd.**  
**Corinne Venot**

Senior Director Business Development

Biologist by training with a PhD from the University of Pierre & Marie Curie in Paris and a Master in biotech & pharma management from ESCP-EAP Paris. She has always been focused in the Oncology field, taking various positions from marketing, early drug discovery, R&D partnering to Business Development & Licensing. Joining Aventis, she was team leader for 8 years in oncology drug discovery projects, moving forward projects from target identification until preclinical candidate, major accomplishment was towards IGF1R project developing small molecule as well as antibody. During 8 years within Sanofi Oncology Division, as director of oncology business opportunities, she was specialized in preclinical/discovery assets with an emphasis on oncobiologics including antibody drug conjugates. She has been playing a major role in building the following licenses and partnerships: in-licensing p53/mdm2, small molecule inhibitor from Ascenta/Univ of Michigan; Dana Farber/Belfer Institute, strategic research collaboration; in licensing of antibody products for ADCs from Oxford Biotherapeutics; Caprion Target identification license & research collaboration; Algeta research collaboration for Thorium RadioImmunoTherapy; several technology deals to build ADC next generation (Innate Pharma BTG technology, Catalent SMART Tag technology, Glykos new linkers, Avipep small format). Within the Immuno-Oncology space the license and research collaboration with Innate Pharma for NK Cell Engagers.

She moved to Servier in 2016, to lead the oncology portfolio licensing activities within the BD&L department. During here time at Servier, she has put in place the Pieris research collaboration and license agreement covering 8 immuno-oncology bispecific anticalins, 2 research collaboration and license agreements on undisclosed targets with Vernalis and the WEHI, as well as a technology license with Transgene for CART Cell therapy. More recently she actively contributed to the Shire Oncology portfolio acquisition Recently joined Beigene, as Senior Director BD&Licensing.



**Deerfield Management****Dave Greenwald**

VP, Business Development

Dave Greenwald, Ph.D. currently serves as Vice President, Business Development at Deerfield Management. In this role, Dr. Greenwald searches for new investment opportunities, supports business development of the Deerfield portfolio companies, and provides hands-on experience to Deerfield's academic collaborations.

Dr. Greenwald was most recently at Johns Hopkins Technology Ventures, where he was Director of Business Development. Dr. Greenwald is a founder of Relay Technology Management, Inc. and coinventor of the Relay Innovation Engine software. Dr. Greenwald was previously Chief Executive Officer of Relay Technology Management and Director of Client Solutions for Decision Resources Group (DRG) after its acquisition of Relay. Dr. Greenwald was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked with the Food and Drug Administration on 510(k) applications for diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and was awarded an NIH Ruth L. Kirschstein National Research Service Award (NRSA) towards his Ph.D. research dissertation on gene therapy for Retinitis Pigmentosa, which he completed at Tufts University School of Medicine. Dr. Greenwald was previously an adjunct faculty at the Tufts University Gordon Institute and The Johns Hopkins Carey Business School where he lectured on Entrepreneurial Finance, Corporate Finance and Life Science Entrepreneurial Ventures.


**MSQ Ventures****Echo Hindle-Yang**

Founder &amp; CEO

Echo is on a mission to make technology accessible by bridging the gap between western companies and Chinese corporations and investors. She is unique in that she has 20 years of experience in cross-border transactions for fortune global companies, such as IBM, Lenovo and J&J. In recent years, making the global movement of the healthcare industry has been her focus. She has been advising hundreds of western pharmaceutical and medical devices companies on advancing their success in China including subsidiaries of Novartis, Daichi, and other top global healthcare companies.

Echo holds an MBA from Duke University and the FINRA Series 7, 63 and 79 securities licenses.

Echo is currently serving on DukeNY Board.

**Celyad****Filippo Petti**


CEO

Filippo Petti joined Celyad in September 2018 as the Chief Financial Officer, and was appointed Chief Executive Officer in April 2019. Prior to joining the Company, Mr. Petti worked in healthcare investment banking both at Wells Fargo Securities and William Blair & Company. Prior to his roles in investment banking, Filippo spent several years in equity research covering U.S. biotechnology companies both at William Blair & Company and Wedbush Securities. He began his career as a research scientist at OSI Pharmaceuticals, Inc. focused on drug discovery and translational research before transitioning into corporate development with the company. Mr. Petti holds a Master of Business Administration from Cornell University, a Master of Science from St. John's University and a Bachelor of Science from Syracuse University.

**Genocea Biosciences, Inc.****Girish Aakalu**

CBO

Girish joined Genocea in December 2018 as Chief Business Officer. In this role, he leads Genocea's business development efforts. His broad skill set spans business development, corporate and R&D strategy, product portfolio management, commercial planning, and alliance management - experience he gained at previous positions at the Ipsen Group, a global specialty biopharmaceutical company, which included Vice President: Global Head of External Innovation, and positions at Pfizer, Inc., which included Executive Director: Head of Strategy, Innovation & Operations for Pfizer's External R&D Innovation team. His previous roles also include business development and oncology pipeline market planning positions at Genentech, Inc. and life science consulting experience at L.E.K Consulting. He received a B.A. in Biophysics with General and Departmental Honors from Johns Hopkins University, a Ph.D. in Cellular and Molecular Neurobiology following an M.S. in Biology from the California Institute of Technology, and has completed executive education in Corporate Governance at Northwestern University - Kellogg School of Management.

**F1BioVentures LLC****Gregory Frost**

Managing Director

Dr. Frost has been Managing Director of F1 BioVentures, LLC since 2015. Prior to F1 BioVentures, he headed the Health Sector of Intrexon Corporation. From 1999 to 2014, Dr. Frost was at Halozyne Therapeutics (NASDAQ HALO), a San Diego public biotechnology company he co-founded, focused on oncology biologics and medication delivery, where he served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002, and CEO since 2010. He has authored multiple peer-reviewed articles and is an inventor on key patents supporting a number of FDA approved biologics. Dr. Frost is a member of the American Society of Clinical Oncology, the American Association for Cancer Research and is registered to practice before the U.S. Patent and Trademark Office. Dr. Frost earned his B.A. in biochemistry and molecular biology from the University of California, Santa Cruz, his Ph.D. in the Department of Pathology at the University of California, San Francisco and postdoctoral research at the Sidney Kimmel Cancer Center. As an entrepreneur, Dr. Frost brought the founding platform technologies to Halozyne and secured the initial capital for the company. His investments in biotechnology span private and public equities. Dr. Frost serves on the Board of directors of BioCom, a member-driven organization serving life science community of Southern California, F1 Oncology Inc, EXUMA Biotechnology SEZC and BioAtla LLC.

**Jemincare Therapeutics Corp.****Guoqiang Jiang**

VP of Business Development

Dr. Jiang is currently the Vice President of Business Development at Jemincare Therapeutics in Princeton New Jersey. Before that, he was the Head of Global Competitive Intelligence and the Senior Director of Global Business Development in Sihuan Pharmaceutical Holding Group. Dr. Jiang worked in Merck & Co for 19 years, first as a scientist in R&D, then a director in Worldwide Business Development, and finally a director in Corporate Finance and Strategy. In his last position at Merck, he supported the strategic planning of products and portfolio, US and Global marketing of new and blockbuster drugs, and licensing and business development. Dr. Jiang performed his postdoctoral training at the Salk Institute of Biological Research as a Fellow of American Cancer Society. He obtained his PhD degree in Environmental Toxicology from the University of California at Riverside.

**BeiGene Ltd.****Guillaume Vignon**

SVP Business Development

Guillaume Vignon is Senior Vice President Business Development at BeiGene, responsible for leading all business development activities, from search & evaluation of partnering opportunities across several therapeutic areas, and all the way through till deal closing.

Guillaume was previously Vice President, Global Head Oncology and Immuno-Oncology Licensing & Business Development at Merck KGaA / EMD Serono. Throughout his career, Guillaume led the closing of complex transactions and forged several strategic partnerships in the fields of Immuno-Oncology, Oncology, Companion Diagnostic, and Antibody Discovery.

Guillaume holds a Ph.D. in Biochemistry and Molecular Biology from the University of Paris 6 / Institut Pasteur, and an MBA from Hult International Business School, Cambridge, MA.

**Innovation Norway****Hanne Mette Dyrлие Kristensen**

Special Advisor, Invest in Norway Life Science &amp; Health

Hanne Mette D Kristensen has 20+ years of experience from C-level position in the industry. She has been working in the oncology space and with technologies spanning from antibodies to RNA to cancer vaccines and immunotherapy. Previous positions include CEO of Targovax, siRNAsense and Diatec Monoclonals, as well as VP Oncology at Bio-Medical Innovation and founder of Oslo Life Science Advisors and board positions. She has an MSc in biochemistry/immunology and a master of technology management from NTNU/NHH/MIT Sloan School of Management. She is currently special advisor and responsible for Life Science / Health at Invest In Norway.

**L.E.K. Consulting****Helen Chen**

Greater China Managing Partner &amp; Head of China Life Sciences

Helen Chen is the Greater China managing partner of L.E.K. Consulting based in Shanghai. She sat on L.E.K.'s Global Leadership Team, the firm's governing board, from 2012 to 2016. Helen has over 30 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000.

Helen is the head of L.E.K.'s China and Asia life sciences practice, with extensive case work and industry experience covering the full biopharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness. In China, she has developed commercial strategies for international med-techs, investment thesis for financial investors, business plans for domestic startups and policy analyses for industry associations.

Helen produced the 2018 special report Heading East: Biopharma International Expansion to China and Asia, and the 2016 Shanghai government commissioned Chinese outbound investment guide From China to the World: An International Investment and Market Access Guide for Chinese Biopharmaceutical Companies. She is a frequent speaker and author on the opportunities and issues in the China healthcare and life sciences, and has been quoted by publications including BioCentury, BioWorld, In Vivo, Wall Street Journal, Financial Times and Forbes Asia.

Prior to joining L.E.K., Helen held senior management roles at a number of technology companies in the U.S. and China. She was an associate director of finance at Genentech (now Roche) and a sales planner at Abbott Laboratories (now AbbVie). She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997.

Helen received her A.B. cum laude in applied mathematics from Harvard University.





**Adaptimmune**  
**Helen Tayton-Martin**  
CBO

Dr. Helen Tayton-Martin has served as our Chief Business Officer since March 2017, having formerly served as our Chief Operating Officer since 2008, a role in which she oversaw the transition of all operations in the company from five to 300 staff, through transatlantic growth, multiple clinical, academic and commercial collaborations and private and public financing through to its Nasdaq IPO.

As our CBO, Dr. Tayton-Martin is responsible for optimizing the strategic and commercial opportunity for Adaptimmune's assets, leading on business development and commercial activities. Her role encompasses all aspects of pipeline and technology assessment, strategic portfolio analysis, integrated program management and commercial planning and partnerships, including the company's strategic partnership with GlaxoSmithKline (LSE/NYSE: GSK) ("GSK").

Dr. Tayton Martin has over 26 years of experience working within the pharma, biotech and consulting environment in disciplines across preclinical and clinical development, outsourcing, strategic planning, due diligence and business development. She co founded Adaptimmune from the former company, Avidex Limited, where she had been responsible for commercial development of the soluble TCR program in cancer and HIV from 2005 to 2008.

Dr. Tayton Martin also serves as a non executive director of Trillium Therapeutics Inc. (NASDAQ and TSX: TRIL). She holds a Ph.D. in molecular immunology from the University of Bristol, U.K. and an M.B.A. from London Business School.

**OrbiMed Advisors LLC****Iain Dukes**

Venture Partner

Iain D. Dukes, D.Phil., is a Venture Partner with OrbiMed. Iain also serves on the Board of Lion Biotechnologies. Most recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as vice president of External Research and Development at Amgen. He has also held positions as president and CEO of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence.

**Moffitt Cancer Center Foundation****James Mulé**


Associate Center Director for Translational Research

Dr. James Mulé is the Associate Center Director for Translational Science, the Michael McGillicuddy Endowed Chair for Melanoma Research and Treatment, and Scientific Director of Cell-Based Therapies at Moffitt Cancer Center. Dr. Mulé, who recently was designated a "Master of Immunology" by the American Association for Cancer Research, serves on Advisory Boards of numerous biotechnology and pharma companies (e.g., Fulgent Genetics, OncoPep, Iovance, Vycellix, Morphogenesis, Vault Nano, and Celgene, among others). Prior to his arrival in Tampa, Dr. Mulé helped to launch and scientifically direct two biotechnology companies in Palo Alto, CA, which were acquired by Sandoz (now Novartis). He also recently prepared both Novartis and Spark Therapeutics for presentations to the FDA, leading to the approval of Kymriah and Luxturna, respectively. Dr. Mulé remains a long-standing special government employee to the FDA (both CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. Dr. Mulé has published nearly 200 articles in the areas of cancer vaccines and cancer immunotherapy.

**Oxford BioMedica Plc.****Jason Slingsby**

CBO

Jason joined Oxford BioMedica in 2015 as Head of Business Development. He has 20 years experience in the biotechnology industry in biologics, vaccines and gene therapy. He has worked in international business development roles at Sosei Co., Ltd. and Intercell AG and was co-founder and CEO of ProtAffin AG, a venture capital backed company in Austria and UK. Jason was awarded a 1st class BA (Hons) in Biochemistry from Magdalen College, Oxford University and also completed a PhD in complex disease genetics from Imperial College London. Jason was awarded an MBA with distinction from London Business School.

**Fortress Biotech****Jason Wang**

Director of Business Development

Jason Wang currently serves as Director, Business Development at Fortress Biotech. In this role, Jason searches for new investment opportunities, supports business development of the Fortress Biotech's portfolio companies, and manages Fortress Biotech's academic collaborations in immune oncology and liver disease. Jason was a Howard Hughes Medical Institute (HHMI) research fellow while earning a M.D. from the University of Illinois, College of Medicine.

**Cello Health BioConsulting, previously Defined Health****Jeffrey Bockman**

EVP, Oncology Practice Head

Jeff is Executive Vice President, Cello Health BioConsulting (Previously Defined Health) and leads the Oncology Practice. Jeff has extensive commercial and strategic perspective on the pharmaceutical and biotech industries. He has directed hundreds of in-depth evaluations of early stage programs and platforms, along with leading many strategic analyses about future Oncology and Immuno-Oncology trends. He often speaks at conferences on scientific/clinical and commercial/strategic issues in cancer, especially on the topic of scientific, clinical and commercial strategies in development of immunotherapies.

Before joining Defined Health, Jeff was a Senior Research Scientist and Research Project Leader in the commercial development of oligonucleotide therapeutics for viral diseases and cancer at Innovir Laboratories; and an Assistant Research Professor at The George Washington University School of Medicine. He has worked closely with two Nobel Prize recipients: Dr. Sidney Altman on ribozymes, and Dr. Stanley Prusiner on prions, and holds various patents in the use of ribozymes as diagnostics and therapeutics.

He received a BA from University of California at San Diego, a PhD in Medical Microbiology from the University of California at Berkeley, and an MA in English/Creative Writing from New York University.

Jeff is a member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the Society for Immunotherapy of Cancer (SITC), the New York Academy of Sciences (NYAS), and the American Society of Gene and Cell Therapy (ASGCT).

**Lilly Asia Ventures****Ji Li**

Venture Partner

Dr. Ji Li has more than 21 years of business development, R&D and investment experience in the biopharmaceutical sector. He is currently Venture Partner at Lilly Asia Ventures (LAV), one of the most successful healthcare venture firms from China. Prior to LAV, Ji was Executive VP and Global Head of Business Development at BeiGene where he oversees the company's partnering activities worldwide, including leading the landmark strategic transaction with Celgene that has transformed BeiGene into a fully integrated biopharmaceutical company. Prior to BeiGene, Ji served as VP of Business Development and Licensing at Merck, where he led the group that was responsible for BD activities of all late-stage inbound and outbound partnering opportunities globally. During this period, Ji has also served, on behalf of Merck, as member of the Board of Director for BeiGene. Prior to Merck, Ji was Executive Licensing Director, External R&D at Amgen where he led the company's product search and evaluation BD team. Earlier in his career, Dr. Li was key member of the Amgen research team discovered and validated the RANKL signaling pathway that has led to the successful development and commercialization of Denosumab, the current standard of care therapy for various bone loss indications with annual sales of about \$4 billion. Ji obtained his B.S. in Pharmacology from Shanghai Medical University and Ph.D. in Neuroscience from Mount Sinai School of Medicine in New York.



**Refuge Biotechnologies, Inc.****Jing Zhao**

CBO

Jing currently serves as the Chief Business Officer of Refuge Biotechnologies with a wealth of experience in global healthcare transactions and financing. He has spent over a decade in pharmaceutical, biotech and healthcare finance working on a full spectrum of strategic transactions at big cap pharma, investment banking, private equity and venture capital.

Jing was previously a Director at Novartis in Basel, Switzerland, leading strategic transactions, acquisitions and divestments totaling over 70 billion dollars. Prior to Novartis, he has also worked in London with Rothschild and Barclays Capital covering a wide range of global healthcare M&A and financings. Jing was most recently head of the healthcare franchise at ICBC RT Capital, a large international private equity and venture capital fund based in Beijing, China, and remains a Venture Partner with them.

Jing graduated in Medicine from Queens' College, University of Cambridge.

**Pfizer, Inc.****John DeYoung**

VP, Oncology Business Development

John is Vice President of Worldwide Business Development for Pfizer Oncology. He is a member of the Oncology Leadership Team and the Worldwide Business Development Leadership Team. John joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development, and Business Development. John received a bachelor's degree in Business from Michigan State University in 1985 and an MBA from the University of Chicago in 1990.

**Eli Lilly and Company****Kuldeep Neote**

VP External Innovation

Kuldeep Neote, Ph.D. is Vice President External Innovation at Eli Lilly and Company and is responsible for integrating external innovation into Lilly Research Labs. He was Senior Director at J&J Innovation Center-Boston responsible for New Venture activities for the Janssen R&D in the East Coast. He has been responsible for several academic and biotech collaboration including two opportunities in Canada and also served as the interim Head of JLABS@Canada. Dr. Neote is trained as a Molecule Biologist with an extensive background in drug discovery. He has been focused in the area of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Throughout his career, he has looked at creative scientific and business development collaborative and partnering opportunities that have resulted in tangible clinical translation of new scientific discoveries working in conjunction with academic and biotech companies. Formerly, Dr. Neote was Research Advisor/Director in Global External R&D at Eli Lilly in Indianapolis, IN and responsible for search and evaluation of Oncology in-licensing opportunities. Prior to Eli Lilly, he was a Discovery Scientist in Pfizer Inc. in Groton, CT. Dr. Neote initiated the Chemokine Receptor Drug Discovery platform that lead to several clinical candidates, and also discovered novel chemokines. Earlier in his career, Dr. Neote cloned one of the first chemokine receptors during his post-doctoral studies in Genentech. Dr. Neote earned her BSc. in Microbial and Cellular Biology at the University of Calgary, Calgary, Canada, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, Toronto, Canada, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.

**Takeda Pharmaceutical Company****Loïc Vincent**

Head, Oncology & Immunology Research Partnerships & Head, Oncology Cell Therapy

Oncology Scientist with international academia/biotech/pharma industry experience, Loïc is a Pharmacologist by initial training with a PhD received in 2003 from the University of Rouen, France. During his thesis, Loïc worked in collaboration with Bayer Pharma and received the Young Scientist Award from the Bettencourt-Schueller's Foundation for his work. Loïc did a post-doctoral fellowship in Oncology at Weill Medical College of Cornell University in NY, where he worked in collaboration with ImClone Systems & OxiGene. Loïc was then appointed Head of Pharmacology and Oncology programs at Endotis Pharma before joining Sanofi as Head of Pharmacology for Sanofi Oncology business unit in 2009. In 2013, Loïc built & led the Immunotherapy Strategy & Execution Team dedicated to shape and implement a strategy for Sanofi to enter the field of immunotherapy, and was then appointed Global Head of Oncology External Innovation.

Loïc joined Takeda in November 2016 and is Head of Oncology & Immunology Research Partnerships. Loïc built several Immuno-Oncology partnerships at Takeda guiding the strategic entry of Takeda into Immuno-Oncology, including cell therapies. Loïc also leads Takeda Cell Therapy Discovery.

Loïc is a board member of the French-American Biotechnology Springboard.

**Tracon Pharmaceuticals****Mark Wiggins**

CBO

Mr. Wiggins is Chief Business Officer for TRACON Pharmaceuticals. Prior to TRACON, he was Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics, and Chief Business Officer at Mpex Pharmaceuticals. Earlier in his career he was at Biogen Idec for eleven years where he held positions including Executive Vice President of Corporate and Business Development, and Vice President of Marketing and Business Development. Mr. Wiggins also previously served as Head of U.S. Business Development at Schering-Plough (now Merck) where he worked for ten years, in addition to earlier roles at Pfizer Pharmaceuticals and Johnson & Johnson. Mr. Wiggins currently serves on the board of directors of Zogenix and SelectION. He earned a B.S. in Finance from Syracuse University and an M.B.A. from the University of Arizona.

**Hutchison China MediTech Ltd.****May Wang**

SVP, Head of BD & Strategic Alliances

Dr. Wang heads all business development and alliance management for the company. She has been instrumental in engaging with, negotiating, executing and very actively liaising with all our development partners, including AstraZeneca, Lilly, Junshi and Innovent etc.

Prior to joining HMP in 2010, Dr. Wang spent 16 years with Eli Lilly and was the Head for Asian Biology Research, responsible for establishing and managing research collaborations in China and Pan-Asia. Dr. Wang has broad drug discovery and development experience spanning several therapeutic areas including infectious diseases, inflammation and oncology. She was a co-inventor for several drug candidates including the blockbuster drug INCIVEK (telaprevir, LY570310) launched in 2011.

Dr. Wang has numerous patents, published more than 50 peer-reviewed articles and has given dozens of seminars and plenary lectures. She received her Ph.D. in Biology from Purdue University, USA.

**Merck KGaA****Matthias Müllenbeck**

Director, Global BD&L, Oncology

Dr. Matthias Müllenbeck is Director Global Licensing & Business Development Oncology at Merck Biopharma, responsible for designing and leading strategic partnering initiatives in the field of oncology and immuno-oncology. Matthias has a track record of leading strategic licensing-, co-development, co-commercialization transactions and multi-asset portfolio acquisitions for various clinical and pre-clinical-stage assets-, platform technologies-, and companion diagnostics. Matthias holds a PhD in immunology from the Humboldt-University of Berlin and a MBA from Kellogg-School of Management Chicago. Prior to joining Merck, Matthias worked as a scientific project leader at the Max-Planck Institute for Infectionbiology Berlin, Germany, and the Albert-Schweitzer Hospital in Lambaréné, Gabon.

**Oppenheimer & Co. Inc.****Michael Margolis**

Co-Head of Healthcare Investment Banking

Michael A. Margolis, R.Ph., joined Oppenheimer & Co. Inc. as Managing Director and its Head of Life Sciences in 2017. Mr. Margolis also serves as Co-Head of Healthcare Investment Banking. He has over two decades of Investment Banking experience in the Life Sciences sectors. Prior to joining Oppenheimer, he served as the Head of Healthcare Investment Banking at Roth Capital Partners, LLC and as a Managing Director at Merriman Holdings, Inc. (also known as Merriman Curhan Ford Group Inc.) Before becoming an Investment Banker, Michael worked at Novartis Pharmaceuticals Corporation in several roles, including as a Director in the Global Business Development and Licensing group. He also served as an Equity Research Analyst at Ursus Capital. He began his career at Eli Lilly & Company as a Senior Pharmaceutical Representative. Mr. Margolis is a registered Pharmacist and holds an M.B.A. from New York University's Stern School of Business and a Pharmacy Degree from Rutgers University, College of Pharmacy.



**Johnson & Johnson Innovation****Michal Preminger**

Head of Johnson & Johnson Innovation, East North America

Michal joined Johnson & Johnson in August 2018 as Head of Johnson & Johnson Innovation Boston. In this role, she leads the Boston innovation center team to build, advance, and manage the External R&D portfolio of co-investments spanning across pharmaceutical, consumer health and medical devices.

Until recently, Michal served as the Executive Director of Harvard University's Office of Technology Development (OTD) Harvard Medical School site, where she was responsible for development and commercialization of technologies emerging from research at HMS laboratories and for the strategy and execution of all industry collaborations. She negotiated agreements with major biopharma, life sciences, food and cosmetics companies to advance the translation of discoveries into products and create a revenue-generating product pipeline, and worked with scientific founders and investors to create new startup companies.

Prior to joining Harvard University's OTD in 2005, Michal held a number of business development and technology development positions at Compugen, most recently as VP of Protein Therapeutics, responsible for the business management of the company's emerging drug discovery pipeline. Previously, she worked in the technology industry in marketing and business development roles, and co-founded a biotechnology startup.

Michal serves on the Scientific Advisory Boards FutuRx Accelerator, and was, until recently, a member of the SAB of Prize4Life and a Member of the Board of Directors of a number of companies, including Compugen, BioArray Genetics, ElmindA and Alma Lasers.

She holds a Ph.D. in Biological Sciences from the Weizmann Institute of Science, an MBA from INSEAD, Fontainebleau, France, and a bachelor degree in Medicine from Hadassah Medical School, Hebrew University, Jerusalem.

**AbbVie, Inc.****Niels Emmerich**

VP, Global Head Search & Evaluation

After joining in 2011 Niels has held several positions at AbbVie, including Global Commercial Leader for a late-stage oncology program, Director and Head of Commercial Business Development for Oncology, Senior Director and Head of Search and Evaluation, Oncology, and most recently Vice President and Global Head of Search and Evaluation. Transactions that Niels was involved in include acquisitions (Pharmacyclics, Stemcentrx), R&D collaborations and license agreements (Argen-X, CALIBR, CytomX, Dong-A-ST, Harpoon, M2Gen, MD Anderson PureMHC, Turnstone, X-Chem) and venture investments.

Prior to joining AbbVie Niels was CEO of BioPheresis, co-founder and COO of immatics, and working for McKinsey & Company.

Niels attended University of Tuebingen and received a Master's in Biology and a Ph.D. in Immunology.

**Aleta Biotherapeutics****Paul Rennert**

President &amp; CSO

Paul Rennert is President & CSO of Aleta Biotherapeutics Inc., based in Natick MA. Aleta is developing transformative technologies for use in cellular therapeutics directed to the treatment of cancer. Paul's industry expertise covers bench to IND and clinical trial development of biological and small molecule drugs for oncology, autoimmunity, chronic inflammation and fibrosis, notably at Repligen Corp. and Biogen Inc. Since 2012 he has focused on building novel biotechnology companies and worked on the genesis of CoStim Pharmaceuticals with MPM Capital, joined with X-Chem Inc to spin out the asset-centric company X-Rx, founded Sugarcone Biotech LLC, and most recently, co-founded Aleta Biotherapeutics and Encipher Biotechnology. He is well known to the immuno-oncology community through his work with diverse biotech companies, academic centers and investors. He has published and patented extensively; his most recent publication is the book "Novel Immunotherapeutic Approaches to the Treatment of Cancer".

**Marker Therapeutics, Inc.****Peter Hoang**

President &amp; CEO

Peter L. Hoang brings over twenty years of immuno-oncology, investment banking, venture capital, and public company executive management experience to Marker Therapeutics, Inc., serving most recently as President & CEO of TapImmune Inc. (Nasdaq: TPIV), one of the predecessor companies that merged to form Marker Therapeutics. He has also served as Senior Vice President of Business Development & Strategy at Bellicum Pharmaceuticals (Nasdaq: BLCM). Previously, as the Managing Director of Innovations at The University of Texas MD Anderson Cancer Center, he headed the new venture formation and development effort for the institution. There, he led the commercialization of MD Anderson's Sleeping Beauty transposon-based CAR-T program, resulting in the largest public company-to-academic research institution upfront deal in history. Before joining MD Anderson, Mr. Hoang was a Managing Director and head of healthcare mergers & acquisitions advisory for CIT Group (NYSE: CIT). He also served as a senior investment banker in the M&A departments at Oppenheimer, J.P. Morgan, Merrill Lynch, and Deutsche Bank. He earned an M.B.A. with high honors distinction from the Anderson School of Management at UCLA and a B.A. from Yale University.

**Astellas Pharma, Inc.****Peter Sandor**

VP, Oncology Therapeutic Area Head for Marketing Strategy

Peter Sandor is Vice President and Global Therapeutic Area Head of Oncology/Marketing Strategy for Astellas Pharma. In this role, Peter provides commercial leadership for project's within the oncology therapeutic area and play an integral role in expansion of Astellas' presence in oncology.

Peter has 20 years of progressive marketing experience. He was recently the Vice President, Global Marketing Oncology at Amgen responsible for the successful realization of the commercial potential for Amgen's oncology assets. Prior to Amgen, he has held different positions at Bayer Healthcare, including Head of Strategy and Portfolio Management Specialty Medicine, Commercial Development and Life Cycle Management Global Oncology. He also worked for Berlex Laboratories as the lead of the global launch team for a key oncology compound, and held multiple marketing roles with Schering AG in Germany and Hungary.

Peter started his career in bench research as a scientific advisor of the Hungarian Academy. He received his MDS Marketing and MBA from Middlesex University, London and Faculty of Business and Economy, University of Pécs, Hungary, and his MD from University of Pécs, Hungary.

**X-Chem, Inc.****Prem Das**

Executive Advisor, BD & Strategy

Prem Das is a consultant, specializing in business development and strategic planning. Since early 2016, he has been Executive Advisor to X-Chem Inc. and has been directly responsible for five major transactions with big pharma, in addition to indirect roles in other deals and in strategic planning. His prior background includes managing academic technology transfer offices, biotechnology business development, and basic research. Until late 2015, he headed the Office of Research and Technology Ventures at Dana-Farber Cancer Institute (DFCI), growing DFCI's research business development, enhancing relationships with the corporate sector, generating sponsored research funding, and commercializing DFCI discoveries. Before joining DFCI, Prem was involved in starting up companies and consulting for biotechnology companies and academia for several years. He also served as Senior Vice President for Technology Alliances at Praecis Pharmaceuticals, where his business development efforts led to the acquisition of the company by Glaxo-Smith Kline in 2007. Prem has led the Office of Technology Licensing at Harvard Medical School and the Office of Industrial Affairs at Memorial Sloan-Kettering Cancer Center. In addition, he has worked at Cadus Pharmaceuticals and co-founded Heartland BioTechnologies. During his academic research career, Prem published in various areas of biology and chemistry. He received his MSc in chemistry from IIT/Kanpur in India and his PhD in biological chemistry from MIT.


**AbbVie, Inc.****Rafael Labrador**

Marketing Director, Market Access Oncology

Raf Labrador joined AbbVie in 2015 to lead AbbVie Oncology's integrated market access strategy for the U.S. His team led the market access launches of Venclexta, AbbVie's hematology product in collaboration with Genentech, through multiple indication approvals in hematology, and has responsibility for AbbVie's near term pipeline assets. Prior to joining AbbVie, Raf spent eight years with GlaxoSmithKline holding oncology focused commercial positions in market access, global marketing, and US brand marketing. Prior to his work in industry, Raf spent seven years as a biopharma strategy consultant with a focus in oncology, advising biopharma and life sciences investor clients on corporate strategy, opportunity assessment, and licensing/acquisitions.

Raf holds a BA from the University of Chicago and an MBA from the Tuck School at Dartmouth.



**The Mark Foundation for Cancer Research****Ryan Schoenfeld**

Senior Scientific Director

Ryan Schoenfeld is an expert in medicinal chemistry with extensive experience working across functional boundaries in data science and disease biology. Over the course of 15+ years as a scientific leader in the pharmaceutical industry and nonprofit sectors, Ryan has played a major role in the discovery and advancement of four novel small molecule therapeutics to human clinical trials. He is the author of numerous peer-reviewed scientific publications and is a named inventor on over 25 patents.

Ryan was Senior Director of Data Sciences at Janssen Pharmaceutical Companies of Johnson & Johnson, where he built and led a large global team of data scientists who delivered high impact machine learning and AI-based solutions for a wide range of problems across all therapeutic areas, including oncology. Prior to his time at J&J, Ryan was a Scientific Director at the CHDI Foundation, where he pursued therapeutics for Huntington's disease, directing teams of global collaborators in medicinal chemistry, chemical biology, structural biology, imaging biomarkers, and stem cell research. Earlier in his career, Ryan worked for Roche Pharmaceuticals where he led medicinal chemistry and chemical biology projects across several different therapeutic areas, coordinated global research informatics initiatives, and oversaw all North America-based discovery chemistry and biology outsourcing with contract research organizations.

Ryan received a PhD in Chemistry from Cornell University studying organic synthesis with Professor Bruce Ganem, and a BS in Chemistry from California Polytechnic State University. Ryan joined The Mark Foundation for Cancer Research in 2018.

**MPM Capital, Inc.****Shinichiro Fuse**

Managing Director

Dr. Shinichiro (Shin) Fuse is focused on advancing MPM's investment identification, due diligence and business development activities. He is also an investment committee member of MPM's oncology-only crossover investment strategy (both public and private equities). Additionally, Shin supports MPM's relationship with Astellas and is a board observer for CODA Biotherapeutics and Repare Therapeutics.

Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing. Previously, he was an Engagement Manager at Campbell Alliance (now Syneos Health) as a management consultant to biotech and pharma clients. Prior to joining Campbell Alliance, he was an Associate at PureTech Ventures, where he focused on venture creation activities in the microbiome space (Vedanta Biosciences). He also serves as a columnist and contributing writer for Nikkei Biotech, the leading journal covering the biotech industry in Japan.

Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.


**Gurnet Point Capital****Sophie Kornowski**

Senior Partner

Dr. Sophie Kornowski joined Gurnet Point Capital in 2018 from Roche, a leading healthcare company based in Switzerland, where she was Executive Vice-President, global Head of Partnering. In this role, Dr. Kornowski developed and maintained over 200 external partnerships with research institutions, Biotech, Pharma and Healthcare Information Technology companies worldwide. During her tenure, Roche Partnering completed over 50 deals per year. Sophie was a member of Roche Extended Global Executive Committee and a member of the boards of Chugai. Previously, for five years Dr. Kornowski was General Manager of Roche France, a major affiliate of the Roche group.

Earlier in her career Dr. Kornowski spent 11 years in various leadership roles at Merck in the United States, France and Israel and in the early years of her career worked at Abbott and Sanofi, in France and the United States.

Dr. Kornowski has a Doctorate in Pharmacy from Rene Descarte University in Paris and an MBA from the University of Chicago Booth.

**Lazard Ltd.****Stephen Sands**

Vice Chairman Investment Banking &amp; Chairman Global Healthcare Group

Stephen Sands, Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group at Lazard, has built a 25-year career providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally. Prior to joining Lazard, a financial advisory and asset management firm, Stephen was a Partner in the health care practice of McKinsey & Company. During his career, he has co-founded two life sciences companies: Enzytech (acquired by Alkermes) and Opta Food Ingredients (acquired by Stake Technology). Stephen has also served as director on the boards of several life sciences companies, including National Imaging Associates, Inc. (Acquired by Magellan Health Services company) and Isogen LLC (acquired by Monsanto). He currently is a director on the board of Cognition Therapeutics (Alzheimer's disease).

Stephen is a frequent keynote speaker and panelist on trends in the biopharmaceutical and health care sectors at prominent industry events. He is a member of the Rockefeller University Counsel; Washington University (St. Louis) School of Engineering & Applied Science National Counsel, National Campaign Committee and New York Regional Cabinet; Columbia University Science Advisory Committee; Rand Corporation Health Board of Advisors; and a trustee and co-chair of the nominating and governance committee of the New York Hall of Science. In 2008, he received the New York Biotechnology Association's inaugural The Cures Start Here Business Leader of the Year Award, and in 2014, he was recognized with a Washington University (St. Louis) Alumni Achievement Award.

Stephen earned a B.A. in Biology from Oberlin College, a B.S. and M.S. in Chemical Engineering from Washington University in St. Louis, and a M.B.A. in Finance from New York University.

**Nextech Invest Ltd.****Thilo Schroeder**

Partner

Thilo Schroeder, Ph.D. is Partner at Nextech Invest Ltd., a global venture fund focused on investing in leading oncology companies. Prior to joining Nextech Invest in 2012, Dr. Schroeder worked in research specializing on the development of Designed Ankyrin Repeat Proteins (DARPs) as specific protein inhibitors (licensed to Molecular Partners / SWX:MOLN). He acquired expertise in molecular biology as an Intern at Micromet Ltd. (now Amgen) and during his studies at the University of Sydney. Dr. Schroeder currently serves as board member of Revolution Medicines, IDEAYA Bioscience, ImaginAb and board observer of Peloton Therapeutics and Black Diamond Therapeutics. He is a prior board member of Blueprint Medicines (NASDAQ:BPMC), SiROP Global, and board observer of Traccon Pharmaceuticals (NASDAQ:TCON). He holds a Ph.D. in biochemistry from the University of Zurich in Switzerland, a M.Sc. in biotechnology from the Ecole de Supérieure de Biotechnologie de Strasbourg in France, and a B.Sc. in biology from the Technical University of Darmstadt in Germany.

**Compass Therapeutics LLC****Thomas Schuetz**

Co-Founder &amp; CEO

Dr. Schuetz, M.D., Ph.D., is the Co-Founder and Chief Executive Officer of Compass Therapeutics, LLC. Previously, Dr. Schuetz was a Venture Partner at OrbiMed where he co-founded Audentes, now a publicly traded company where he remains a Director. Also at OrbiMed, he was responsible for the investments in Enobia, Arteaus, and Relypsa where he served as a Director at each of these companies. Enobia was acquired by Alexion in 2011, Arteaus was acquired by Eli Lilly in 2014, and Relypsa was acquired by Galenica in 2016. Dr. Schuetz has multiple years of clinical strategy, development and operations experience including roles as Chief Medical Officer of Therion Biologics Corporation, a cancer vaccine company, and the Vice President of Clinical Affairs at Transkaryotic Therapies, a company acquired by Shire.

Dr. Schuetz completed his medical training at Massachusetts General Hospital, where he served as the Chief Medical Resident, and completed his medical oncology fellowship at the Dana-Farber Cancer Institute. Dr. Schuetz holds a B.S. in chemistry from Xavier University, an M.D. from Harvard Medical School and a Ph.D. in Genetics from Harvard University. Dr. Schuetz is Board Certified in Medical Oncology.

**Caribou Biosciences, Inc.****Timothy Herpin**

CBO

Timothy Herpin Ph.D., is CBO of Caribou Biosciences where he leads the company's efforts in the areas of strategic partnerships, licensing agreements, and other value creation opportunities. Prior to Caribou, Tim was Vice President, Head of Transactions at AstraZeneca and led a group of business development professionals involved in all aspects of transactions negotiation and execution. Tim joined AstraZeneca in 2011 as Vice-President, Strategic Partnering and Business Development, initially for Neuroscience and subsequently for Oncology. Prior to AstraZeneca, Tim spent eight years in the business development organization at Bristol-Myers Squibb covering both search and evaluation as well as transaction in multiple disease areas. Before his business development career, Tim worked in R&D at Bristol-Myers Squibb, Aventis and Pharmacoepia. Tim grew up in Paris and is a graduate of Ecole Polytechnique in France. He also holds a Ph.D. in organic chemistry from University College London and an MBA in Finance from NYU Stern.

**Cleveland Clinic**  
**Yogen Sauntharajah**

Professor of Medicine, Co-Leader of the Developmental Therapeutics Program & Staff Physician

Yogen Sauntharajah is a Professor of Medicine, Staff Physician and Co-Leader of the Developmental Therapeutics Program at the Taussig Cancer Institute of Cleveland Clinic and Case Comprehensive Cancer Center in Cleveland, and founding-scientist of EpiDestiny. His research and drug development efforts focus on exploiting a fundamental and common distinction between normal and malignant self-replication, that enables selective termination of malignant but not normal self-replication even if p53 is mutated. The same treatments can moreover trigger immune-recognition of cancers (convert tumors from 'cold' to 'hot') while sparing immune-effectors, and are therefore a rational platform for increasing the spectrum of responses to immune checkpoint blockade. An important co-focus of the Sauntharajah group is non-cytotoxic epigenetic induction of fetal hemoglobin, for sustainable, life-long disease modification of the beta-hemoglobinopathies.

**BOHE Angel Fund**  
**Yuwen Liu**

Founding Partner

Founding Partner of BOHE Angel Fund, a 200M RMB fund jointly invested by Wuxi Apptec, Hengrui, Simcere, TigerMed and BGI, etc. This is the first angel fund focusing on healthcare technology-driven start-ups in China, with Xiaodong Wang and Yigong Shi sitting on its scientific advisory board. It has invested into XinKangHe biological, Transcriptic, SmartNucleide, Athelas Therapeutics, CoolLing Biotech, and HighField BioPharmaceutical covering drug discovery, diagnostic and innovative service solutions.

Before she sets up this fund, she was Chairwoman & CEO then executive director of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY) for 9 years, when she was also Investment Committee Member for BioVENTURE Fund, and Board Director of Innovent, Admera Health, Chiral Quest, GenePharma, Reproposing and BrightGene, and Chairwoman of Qiagen (Suzhou) Translational Medicine and Suzhou BioTOP Biotech. She joined the company as EVP in 2005, was instrumental in building BioBAY to be one of the fastest growing biotech clusters serving ~400 biotech startup companies.

She started her career as QA Engineer for Capsugel in 1997, then moved up to QC manager, QA/QC manager and BD manager. In 2003, she joined Perrigo as first Chief Representative to set up its China operation

She graduated from China Pharmaceutical University with master degree in Pharmaceutics and Master of Management at Fudan University and Norwegian Management School BI. She is a licensed pharmacist.



**ADDRESS**

3150 Almaden Expressway,  
Suite 250  
San Jose, 95118  
United States

**WEBSITE**

www.anixa.com

**E-MAIL**

cabushaaban@anixa.com

**PHONE**

+1 408 708 9808

**COMPANY TYPE**

Public

**TICKER**

[NASDAQ: ANIX]

**SECTOR**

Biotechnology

**FOUNDED**

1982

## **Anixa Biosciences, Inc.**

### **COMPANY PROFILE**

Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa is developing a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T. Its Cchek™ liquid biopsy technology is a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body's immune response to the presence of a malignancy. This technology enables cancer detection in its earliest stages in efforts to treat patients when the disease is most curable. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

### **MANAGEMENT TEAM**

- Dr. Amit Kumar, PhD - Chairman, President & Chief Executive Officer
- Michael Catelani - Chief Operating Officer and Chief Financial Officer
- John Roop - Senior Vice President of Engineering
- Anthony Campisi - Vice President of Engineering

### **PRODUCTS**

Product #1

#### **Ovarian Cancer CER-T (CAR-T)**

Chimeric endocrine receptor t-cell therapy targeting Follicle Stimulating Hormone Receptor, a protein receptor only found on ovary cells in adult women. Anticipate IND filing in 2019.

Opportunity #1

#### **Ovarian Cancer CER-T (CAR-T)**

Collaborating with the Moffitt Cancer Center to complete pre-clinical studies and Phase I trial.



**BeiGene**

**ADDRESS**  
55 Cambridge Parkway  
Suite 700W  
Cambridge, 02142  
United States

**WEBSITE**  
www.beigene.com

**E-MAIL**  
bd@beigene.com

**PHONE**  
+1 877 828 5568

**COMPANY TYPE**  
Public

**TICKER**  
[NASDAQ: BGNE]

**SECTOR**  
Biotechnology

**FOUNDED**  
2010

**BeiGene Ltd.**

**COMPANY PROFILE**

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of approximately 2,400 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID®(lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.

**MANAGEMENT TEAM**

- John V. Oyler, Chairman - Co-founder & CEO
- Xiaodong Wang - Chairman of Scientific Advisory Board & Co-founder
- Xiaobin Wu - GM of China and President of BeiGene Ltd.
- Howard Liang - CFO & Chief Strategy Officer
- Eric Hedrick - Chief Advisor
- Yong (Ben) Ben - CMO, Immuno-Oncology
- Jane Huang - CMO, Hematology
- Lai Wang - SVP and Head of APAC Clinical Development, Global Clinical Operations, and Biometrics
- Guillaume Vignon - SVP and Head of Business Development
- Josh Neiman - Head U.S. Commercial
- Scott Samuels - SVP General Counsel
- Todd Yancey - SVP Global Medical Affairs & New Market Development
- Wendy Yan - SVP and Global Head of Regulatory Affairs

**PIPELINE**

	ASSETS	PROGRAMS (MECHANISMS)	DOSE ESC. PH1a	DOSE EXPANSION PH1b	PH2*	PIVOTAL PH2**	PH3	FILED	LEAD INDICATIONS	COMMERCIAL RIGHTS	
Internally-Developed	zanubrutinib (BTK)	monotherapy	[Progression]					[Phase 3]	[Phase 3]	• R/R MCL, R/R CLL/SLL (NDAs accepted) • R/R WM • WM, 1L CLL/SLL, R/R CLL/SLL • R/R MZL • R/R FL	Global
		GAZYVA® combo (CD20)	[Progression]					[Phase 3]	[Phase 3]		
	tislelizumab (PD-1)	monotherapy	[Progression]					[Phase 3]	[Phase 3]	• R/R HL (NDA accepted) • 2L+ UC (pivotal Ph2) • 2L NSCLC, 1L HCC, 2L ESCC • 2L/3L HCC	Global (heme malignancies) Asia ex-Japan (solid tumors)*
		chemo combo (Chemo)	[Progression]					[Phase 3]	[Phase 3]	• R/R NK/T-cell lymphoma • 1L Sq NSCLC, 1L Non-Sq NSCLC	
		pamiparib combo (PARP)	[Progression]					[Phase 3]	[Phase 3]	• 1L GC, 1L ESCC • Solid tumors	Global
		zanubrutinib combo (BTK)	[Progression]					[Phase 3]	[Phase 3]	• B-cell malignancies	
	pamiparib (PARP)	monotherapy	[Progression]					[Phase 3]	[Phase 3]	• Solid tumors • 3L gBRCA+ ovarian cancer • 2L platinum-sensitive ovarian cancer maintenance • 1L platinum-sensitive gastric cancer maintenance	Global
		TMZ combo (Chemo)	[Progression]					[Phase 3]	[Phase 3]	• Solid tumors	
		RT/TMZ combo (RT/Chemo)	[Progression]					[Phase 3]	[Phase 3]	• Glioblastoma	
	lifirafenib (RAF Dimer)	monotherapy	[Progression]					[Phase 3]	[Phase 3]	• B-Raf- or K-RAS/N-RAS-mutated solid tumors • B-Raf- or K-RAS/N-RAS-mutated solid tumors	Global
BGB-A333 (PD-L1)	monotherapy and tislelizumab combo (PD-1)	[Progression]					[Phase 3]	[Phase 3]	• Solid tumors	Global	
BGB-A425 (TIM-3)	monotherapy and tislelizumab combo (PD-1)	[Progression]					[Phase 3]	[Phase 3]	• Solid tumors	Global	
In-Licensed	REVLIMID®	(IMiD)	[Progression]					[Phase 3]	[Phase 3]	• R/R MM (marketed), NDMM (marketed), R/R NHL (Ph3)	China
	ABRAXANE®	(albumin-bound paclitaxel)	[Progression]					[Phase 3]	[Phase 3]	• Breast cancer	China
	VIDAZA®	(hypomethylating agent)	[Progression]					[Phase 3]	[Phase 3]	• MDS, AML with 20-30% bone marrow blasts, CMMoL	China
	avadomide	(CC-122, CELMoD)	Planned (in Ph2 ex-China by Celgene)							• NHL	China
	sitravatinib	(multi-kinase inhibitor)	[Progression]					[Phase 3]	[Phase 3]	• Solid tumors	Asia ex-Japan, AU, NZ <sup>2</sup>
	ZW25	(bispecific HER2 antibody)	Planned (in Ph1b ex-China by Zymeworks)							• HER2+ gastric, breast and other cancers	Asia ex-Japan, AU, NZ <sup>2</sup>



**ADDRESS**  
Solvegatan 41  
Lund, 223 70  
Sweden

**WEBSITE**  
www.bioinvent.com

**E-MAIL**  
info@bioinvent.com

**PHONE**  
+46 46 286 85 50

**COMPANY TYPE**  
Public

**TICKER**  
[OMAX:BINV]

**SECTOR**  
Biotechnology

**FOUNDED**  
1997

## BioInvent International AB

### COMPANY PROFILE


BioInvent International AB (OMXS: BINV), is focused on the discovery and development of novel and first-in-class and best-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program BI-1206 is currently in Phase I/IIa for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells of the tumor microenvironment relevant to solid and hematologic cancers, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials.

### MANAGEMENT TEAM

- Martin Welschof - CEO
- Björn Frenhéus - CSO
- Andrés McAllister - CMO
- Stefan Ericsson - CFO
- Kristoffer Rundenholm Hansson - SVP, Technical Operations

### PIPELINE

## BIOINVENT PIPELINE



**ADDRESS**

Rue Edouard Belin 2  
Mont-Saint-Guibert, 1435  
Belgium

**WEBSITE**

[www.celyad.com](http://www.celyad.com)

**E-MAIL**

[pvanhavere@celyad.com](mailto:pvanhavere@celyad.com)

**PHONE**

+32 10 394 207

**COMPANY TYPE**

Public

**TICKER**

[EBR: CYAD]

**SECTOR**

Biotechnology

**FOUNDED**

2007

## Celyad

### COMPANY PROFILE

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies and utilizes its expertise in cell engineering to target cancer. Celyad's CAR-T cell autologous and allogeneic platforms have the potential to treat a broad range of solid and hematologic tumors. After having demonstrated safety, its lead oncology autologous CAR-T therapy CYAD-01 (CART NKG2D) is now currently being evaluated in several Phase I clinical trials to assess the clinical activity of multiple administrations of autologous CYAD-01 cells in solid cancer (metastatic colorectal cancer) and hematological tumors (acute myeloid leukemia) with or without being concurrently administered with standard-of-care treatments (preconditioning chemotherapy). Concomitantly, Celyad is developing CYAD-101, first-in-class, investigational, non-gene edited, allogeneic (donor derived) CAR-T therapy co-expressing the CAR-T NKG2D and the novel inhibitory peptide TIM (T cell receptor [TCR] Inhibiting Molecule). The expression of TIM reduces signaling of the TCR complex and could therefore reduce or eliminate Graft versus Host Disease (GvHD). CYAD-101 is evaluated in a Phase I trial for the treatment of patients with mCRC. Preliminary results are expected in second half of 2019. Celyad was founded in 2007 and is based in Mont-Saint-Guibert, Belgium, and New York, NY. Celyad's ordinary shares are listed on the Euronext Brussels and Euronext Paris exchanges, and its American Depository Shares are listed on the Nasdaq Global Market, all under the ticker symbol CYAD.

### MANAGEMENT TEAM

- Filippo Petti - CFO
- David Gilham - VP R&D
- Frédéric Lehmann - VP Clinical Development and Medical Affairs
- Jean-Pierre Latere - COO
- Philippe Dechamps - Chief Legal Officer
- Philippe Nobels - VP HR



**ADDRESS**

245 First St. 3rd Floor  
Cambridge, 02142  
United States

**WEBSITE**

www.compasstherapeutics.com

**E-MAIL**

partners@compasstherapeutics.com

**PHONE**

+1 617 500 8099

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology

**FOUNDED**

2015

## Compass Therapeutics LLC

### COMPANY PROFILE

Compass Therapeutics is a clinical-stage biotechnology company targeting the immune synapse with a new generation of antibody therapeutics that display novel epitope-driven biology. Compass' approach leverages comprehensive mapping of each target and high-throughput identification of antibodies with the desired effect. Compass' proprietary StitchMabs platform enables rapid generation and screening of multi-specific antibodies in countless combinations that can be tailored for each specific biological application. The company's lead product candidate, CTX-471, is undergoing Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors.

### MANAGEMENT TEAM

- Thomas Schuetz, MD, PhD - Co-Founder and CEO
- Vered Bisker-Leib, PhD - Chief Business Officer
- Lynne Sullivan - Chief Financial Officer
- Michael Schmidt, PhD - Senior VP and Head of Research
- Greg Zarbis-Papastoitsis, PhD - Senior VP, Process and Manufacturing

### FINANCIAL SUMMARY

The company has completed \$132 million Series A financing. The financing was led by OrbiMed Advisors and included F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Ulysses Holdings, Borealis Ventures, Alexandria Venture Investments and Biomed Realty Ventures.

### PRODUCTS

Product #1


**CTX-471**

CTX-471 is a fully human, IgG4 agonist antibody of CD137 (4-1BB or TNFSF9) which targets a unique epitope on CD137 and has been optimized to induce potent tumor cell death via activation of immune system. CTX-471 profile has been optimized for activity across various syngeneic in vivo models.

Product #2

**CTX-8573**

This is a first-in-class NKp30 x BCMA (NK cell engager) which induces cytokine production, NK cell proliferation and potent tumor cell killing of target cells with high, medium, and low BCMA expression.

**ADDRESS**

2 Yozma St.  
Tirat-Carmel, 3903202  
Israel

**WEBSITE**

www.convergent-rnr.com

**E-MAIL**

Zeev.H@Convergent-RNR.com

**PHONE**

+972 4 858 4546

**COMPANY TYPE**

Private

**SECTOR**

Medical Devices

**FOUNDED**

2010

## Convergent R.N.R Ltd.

### COMPANY PROFILE

Convergent R.N.R (CRnR) is an Israeli company engaged in developing a lens based system attached to an ordinary X-ray source (sources which are commercially used for X-ray imaging) to converge X-rays of kV range of photon energy towards a volume of interest for the purpose of radiotherapy and radiosurgery of tumors. The technology is based on a proprietary X-ray lens design, which converges only the 60 keV photon energies, all other energies (either lower or higher than 60 keV) are absorbed by the metal single crystals that construct the lens.

CRnR collaborate with MD Anderson Cancer Center (MDACC), the largest and most prestigious world Cancer Medical Center, that performs the medical tests of our technology.

The lenses are serving as a platform for variety of medical applications:

Radiotherapy and Radiosurgery (The first implementation of our technology).  
Pediatrics Cancer Treatment.  
Converging-imaging.  
Imaging while Treating.  
New approach for Breast Cancer (3 Dimensions Monochromatic Imaging & Treatment by immediate "sniping" at the tumor).  
Denervation (Heart Fibrillation, Renal Denervation).  
Brain-disorders in a single shot (Parkinson, etc..).  
Wet-AMD (Age-related Macular Degeneration) and Eye Melanoma.  
GNP (Gold Nano-Particles) radio sensitization.  
Mobile/Transportable Systems (including Off-Road systems).

### MANAGEMENT TEAM

- Ze'ev Harel - Managing Director.
- Prof. Ze'ev Burshtein - Chief Scientist.
- Dr. Aharon Bar-David - Chief Physicist.

### FINANCIAL SUMMARY

FUNDING TO DATE: Total previously invested \$6,000,000. CURRENT INVESTORS: Angels from Israel, Denmark and USA. FINANCING SOUGHT: \$10,000,000 - \$30,000,000

**ADDRESS**

BritCay House 236 Eastern  
Avenue, P.O. Box 10315  
Georgetown, Grand Cayman  
KY1-1003  
Cayman Islands

**WEBSITE**

[www.exumabio.com](http://www.exumabio.com)

**E-MAIL**

[wli@exumabio.com](mailto:wli@exumabio.com)

**PHONE**

+1 345 232 0566

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology

**FOUNDED**

2016

## EXUMA Biotechnology SEZC

### COMPANY PROFILE

EXUMA Biotechnology is a clinical stage immuno-oncology company pioneering the development and commercialization of logic gate-controlled T cell therapies for the treatment of cancer in the Greater China markets. The Company's platform technologies have generated a continuous pipeline of novel product candidates that feed into proprietary manufacturing systems to generate genetically engineered T cells capable of identifying and killing tumor cells. Product candidates are being developed on two delivery solutions, CCT3 and CCT4, which are intended to serve distinct market segments.

The Company believes its logic gate-controlled CAR-T cell technology may achieve greater specificity against solid tumors while minimizing damage to normal tissues in the body. To date, CCT301-38-AXL and CCT301-59-ROR2 CAR-T cell therapies have been tested in metastatic renal cell carcinoma through investigator-initiated trials (IITs) in a precision medicine directed umbrella trial. The Company plans to expand these clinical product candidates into multicenter trials under a centralized regulatory pathway in 2019, with a third undisclosed target intended for first in human filing by year end. The Company's next generation CCT4 CAR-T delivery systems are currently in development to provide broader patient access through reduced cost and complexity of patient care.

EXUMA Biotechnology was formed in 2016 as a Cayman Special Economic Zone Company, with capitalization and exclusive technology licenses from F1 Oncology, Inc with recent asset acquisitions from the PRC. The Company's wholly owned subsidiaries, EXUMA Biotechnology Hong Kong Ltd. and Shanghai EXUMA Biotechnology Ltd., are responsible for development, manufacturing, quality, clinical, regulatory, and commercial operation with facilities located in Shanghai and Shenzhen, PRC.



**ADDRESS**

Joukahaisenkatu 6  
Turku, 20520  
Finland

**WEBSITE**

www.faron.com

**E-MAIL**

info@faron.com

**PHONE**

+358 2 469 5151

**COMPANY TYPE**

Public

**TICKER**

[LON: FARN]

**SECTOR**

Biotechnology  
Pharmaceuticals/Licensing

**FOUNDED**

2007

## Faron Pharmaceuticals Ltd.

### COMPANY PROFILE

Small but tough. Faron is a clinical stage biotech tackling some of the worst diseases on the planet such as ARDS, pancreatic and colorectal cancer, glioblastoma and tuberculosis. We are backed up with world leading science in vascular integrity, leucocyte migration and tumor biology, accompanied with exceptional dedication to the cause.

### MANAGEMENT TEAM

- Markku Jalkanen - CEO
- Yrjö Wichmann - CFO
- Matti Karvonen - CMO
- Juho Jalkanen - CDO
- Maria Lahtinen - Director Supplies
- Jami Mandelin - Director R&D

### FINANCIAL SUMMARY

Faron Pharmaceuticals is publicly traded company on the London Stock Exchange Alternative Investment Market (LSE AIM) under the ticker FARN with numerous successful financial rounds as well as grant funding and clinical development milestones. All together Faron has so far raised approximately \$70 million in capital.

### PIPELINE

**Traumakine®**

Enhancing the endothelial barrier function against ischaemic conditions



Program	Program indication	Research	Preclinical development	Phase I/II	Phase III	MAA/BLA	LAUNCH	Partnered
---------	--------------------	----------	-------------------------	------------	-----------	---------	--------	-----------

**Acute Respiratory Distress Syndrome (ARDS)**



FP-1201-Iyo Interferon β	CD 73 ARDS EU							
FP-1201-Iyo Interferon β	CD 73 ARDS Japan							
FP-1201-Iyo Interferon β	CD 73 CALIBER Global							

\* Subject to regulatory discussions and approvals and partnership discussions

**Multi Organ Failure (MOF)**



FP-1201-Iyo Interferon β	CD 73 RAAA							
--------------------------	------------	--	--	--	--	--	--	--

**Clevegen®**

Switches immune suppressive M2 macrophages to immune stimulating M1 macrophages



Program	Program indication	Research	Preclinical development	Phase I/II	Phase III	MAA/BLA	LAUNCH	Partnered
---------	--------------------	----------	-------------------------	------------	-----------	---------	--------	-----------

**Immuno-oncology**



FP-1305 Antibody	Clever-1 Hepatobiliary cancers							
FP-1305 Antibody	Clever-1 Pancreatic cancer							
FP-1305 Antibody	Clever-1 Ovarian cancer							
FP-1305 Antibody	Clever-1 Colorectal cancer							
FP-1305 Antibody	Clever-1 Metastatic melanoma							
FP-1305 Antibody	Clever-1 Glioblastoma							





**ADDRESS**

100 Acorn Park Drive  
Cambridge, 02140  
United States

**WEBSITE**

www.genocea.com

**E-MAIL**

business.development@  
genocea.com

**PHONE**

+1 617 876 8191

**COMPANY TYPE**

Public

**TICKER**

[NASDAQ: GNCA]

**SECTOR**

Biotechnology

**FOUNDED**

2008

## Genocea Biosciences, Inc.

### COMPANY PROFILE

As we say at Genocea, “targets matter.” We are currently advancing a growing pipeline of innovative cancer therapies that demonstrate that target – or antigen – selection plays an important role in driving immunotherapy efficacy.

Our unique ATLAS™ technology platform allows us to identify and characterize immunotherapy targets based on each individual’s tumor antigen-specific T cell responses. Using ATLAS, we can both optimize neoantigens for inclusion in our immunotherapies and exclude “inhibitory” neoantigens that appear to exert an immunosuppressive effect on the patient.

Our two lead programs are built from our ATLAS insights:

GEN-009, our neoantigen vaccine for which we are conducting a Phase 1/2a clinical trial across a variety of solid tumor types, and GEN-011, our neoantigen-specific adoptive T cell therapy, for which we intend to file an Investigational New Drug Application in the first half of 2020.

We are currently exploring a variety of partnership opportunities both to accelerate development of GEN-009, GEN-010, GEN-011 and our shared antigen vaccine programs, as well as to expand the applications for our ATLAS technology, including antigen / TCR discovery and ATLAS-enhanced biomarker / drug development.

### MANAGEMENT TEAM

- Girish Aakalu, Ph.D. - Chief Business Officer
- Pamela Carroll, Ph.D. - Senior Vice President, Scientific Strategy and Alliances
- Chip Clark - President and Chief Executive Officer
- Tom Davis, M.D. - Chief Medical Officer
- Diantha Duvall - Chief Financial Officer
- Jessica Baker Flechtner, Ph.D. - Chief Scientific Officer
- Derek Meisner - Senior Vice President, General Counsel
- Narinder Singh - Senior Vice President, Pharmaceutical Sciences and Manufacturing

### PIPELINE

	DISCOVERY	PRE-IND	PHASE 1/2a	PIVOTAL	STATUS & ANTICIPATED MILESTONES
<b>GEN-009</b> 1st Generation Neoantigen Cancer Vaccine	[Progress bar spanning Discovery, Pre-Ind, and Phase 1/2a]				<ul style="list-style-type: none"> <li>• First immunogenicity data in mid-2019</li> <li>• Clinical efficacy data in 2020</li> </ul>
<b>GEN-010</b> 2nd Generation Neoantigen Cancer Vaccine	[Progress bar spanning Discovery and Pre-Ind]				<ul style="list-style-type: none"> <li>• Proprietary vaccine modality</li> </ul>
<b>GEN-011</b> Adoptive T cell therapy	[Progress bar spanning Discovery and Pre-Ind]				<ul style="list-style-type: none"> <li>• IND in 1H 2020</li> </ul>
Shared Antigen Cancer Vaccines	[Progress bar in Discovery]				<ul style="list-style-type: none"> <li>• Novel antigens discovered in CRC, NSCLC</li> </ul>
Vaccines for Cancers of Viral Origin	[Progress bar in Discovery]				<ul style="list-style-type: none"> <li>• Novel antigens discovered for Epstein-Barr Virus</li> </ul>

**ADDRESS**

1601 Trinity Street, Bldg. B,  
Suite 3.322  
Austin, 78712  
United States

**WEBSITE**

www.genprex.com

**E-MAIL**

investors@genprex.com

**PHONE**

+1 877 774 4679

**COMPANY TYPE**

Public

**TICKER**

[NASDAQ: GNPX]

**SECTOR**

Biotechnology

**FOUNDED**

2009

## Genprex, Inc.

### COMPANY PROFILE

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex's initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

### MANAGEMENT TEAM

- Rodney Varner, JD, Chairman and Chief Executive Officer
- Julien L. Pham, MD, MPH, President and Chief Operating Officer
- Ryan M. Confer, MS, Chief Financial Officer

### PRODUCTS

Product #1

#### **Oncoprex™ immunogene therapy (Phase I/II)**

Oncoprex™ immunogene therapy works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.



**ADDRESS**

6048 Cornerstone Ct. West,  
Suite D  
San Diego, 92121  
United States

**WEBSITE**

www.immunicom.com

**E-MAIL**

business@immunicom.com

**PHONE**

+1 858 263 5308

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology  
Medical Devices

**FOUNDED**

2013

## Immunicom, Inc.

### COMPANY PROFILE

Immunicom, Inc. is a privately-held medical technology company located in San Diego, CA focused on developing innovative, non-pharmaceutical approaches for treating cancer, inflammatory diseases, and autoimmune diseases.

Immunicom has received FDA Breakthrough Designation for its non-pharmaceutical solution for treating stage IV metastatic cancer. The solution in development is a blood-filtering technology for Immunicom's proprietary immunotherapy solution, Immunopheresis™. The Immunopheresis™ treatment removes proteins that suppress the immune system and protect tumors. The treatment has the potential to effectively treat a wide variety of cancer types including those that have not responded to other treatment strategies including other drug and biological-based immunotherapy options, and to do so with fewer side effects.

Immunicom seeks to leverage its technology to address unmet medical needs and improve patient access and affordability of cancer and other inflammatory and autoimmune disease treatments around the world.

In May 2019, Immunicom will begin a 170-patient, multi-center, triple-negative breast cancer study in Europe. This pivotal study will include three arms: mono-therapy, combination chemotherapy, and a chemotherapy-only control. In September, 2019, the Company will begin an additional single-center trial in Israel focused on dosing and combination therapy with a checkpoint inhibitor. The Israeli study will cover multiple solid tumor cancer types

### MANAGEMENT TEAM

- Amir Jafri - Chief Executive Officer, Founder
- Stephen Prince - Chief Commercial Officer
- David Lopez, Esp., CPA - Chief Financial Officer
- Adam Ostrowski, M.D. - International Medical Director

Product	Disease Market	POC	Molecule Design	Molecule Mfr.	In-vitro Validation	Animal Safety	Human Safety	Human Efficacy	Regulatory Approval
LW-02	Triple Negative Breast Cancer								
LW-02	Solid Multiple Tumor								
IM-02	Inflammatory disease Post-surgical recovery Auto-Immune								
IM-03	Remove drug side effects								
IM-04	Preventing cancer metastases								
IM-05	Improve quality of life (terminal patients)								



**ADDRESS**

Östermalmstorg 5  
Stockholm, 114 42  
Sweden

**WEBSITE**

www.immunicum.se

**E-MAIL**

info@immunicum.com

**PHONE**

+46 8 732 8400

**COMPANY TYPE**

Public

**TICKER**

[STO: IMMU]

**SECTOR**

Biotechnology

**FOUNDED**

2002

## Immunicum AB

### COMPANY PROFILE

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.

### MANAGEMENT TEAM

- Carlos de Sousa - Chief Executive Officer
- Michaela Gertz - Chief Financial Officer
- Alex Karlsson-Parra - Chief Scientific Officer
- Peter Suenart - Chief Medical Officer
- Sharon Longhurst - Head of CMC
- Margareth Jorvid - Head of Regulatory and QA
- Sijme Zeilemaker - Senior Director Business Development

### FINANCIAL SUMMARY

In November 2018, Immunicum raised \$39 million on Nasdaq Stockholm before issue costs for continued clinical development of ilixadencel through a directed issue and a rights issue.

### PRODUCTS

Product #1  
**Ilixadencel**

Immunicum's lead product ilixadencel is an immune primer containing allogeneic cells specially treated to become inflammatory dendritic cells. The use of allogeneic cells makes the need for patient-specific cells obsolete which allows for the manufacturing of an off-the-shelf product that can be used for injectable, solid tumors.

### PIPELINE

Product & Indication	Combination	Preclinical	Phase I	Phase II	Phase III
<b>Ilixadencel:</b> an off-the-shelf cancer immune primer					
Kidney cancer	Kinase inhibitors	top-line results Q3 2019			
Liver cancer	Kinase inhibitors				
Gastrointestinal stromal tumors	Kinase inhibitors				
Head and neck cancer	Checkpoint inhibitors				
Non-small cell lung cancer	Checkpoint inhibitors				
Gastric cancer	Checkpoint inhibitors				
<b>IMM-2:</b> allogeneic dendritic cells with adenovirus coding for tumor antigens					
<b>IMM-3:</b> optimized CAR-T expansion protocol for improved anti-cancer activity					





**ADDRESS**  
15010 Broschart Road  
Suite 250  
Rockville, 20850  
United States

**WEBSITE**  
www.immunomix.com

**E-MAIL**  
sia@immunomix.com

**PHONE**  
+1 301 968 3501

**COMPANY TYPE**  
Private

**SECTOR**  
Biotechnology

**FOUNDED**  
2006

## Immunomic Therapeutics, Inc.

### COMPANY PROFILE

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over \$315M in licensing revenue that year, the company has now focused on the application of its UNITE™ platform in oncology.

### MANAGEMENT TEAM

- William Hearl - CEO, Chairman of the Board & Founder
- Teri Heiland - Senior Vice President of Research & Development
- Eric Winzer - Chief Financial Officer
- Louise Peltier - Vice President, Regulatory Affairs
- Tim Coleman - Vice President, Operations
- Sia Anagnostou - Senior Director, Corporate Development

### PIPELINE

Program	Therapeutic Area	Indication	Target	Stage of Development					Commercial Rights
				Discovery	Pre-Clinical	Ph. I	Ph. II	Ph. III	
ITI-1000	Oncology	GBM	DC-based pp65 CMV	Series B Funds				ITI	
ITI-1001	Oncology	GBM	pDNA pp65 CMV	Series B Funds				ITI	
ITI-2000	Oncology	HPV+ Tumors	HPV E6/E7	Series B Funds				ITI	
ITI-4000	Oncology	NCP / Gastric	Epstein-Barr Virus	Partner Opportunity				ITI	
ITI-6000	Oncology	HCC	HBV ag + Others	Partner Opportunity				ITI	
ITI-7000	Oncology	Bladder	HER2 + NY - ESO-1	Partner Opportunity				ITI	
ASP-JRCv2.0 <sup>1</sup>	Allergy	Japanese Red Cedar	pDNA					Astellas	
ASP-0892 <sup>2</sup>	Allergy	Peanut	pDNA					Astellas	
ASP-2390 <sup>3</sup>	Allergy	HDM+ other allergens	pDNA					Astellas	
Animal Health <sup>3</sup>	All	All	pDNA					Zenobq	

<sup>1</sup> JRC program active: Astellas conducting IND enabling studies using Improved Immunization vector (single plasmid)

<sup>2</sup> Astellas advancing multiple new allergy programs into clinic and Phase I studies, including House Dust Mite, in 2019/2020

<sup>3</sup> Animal Health Stages NM

**ADDRESS**

25 Science Park, Suite 235 150  
Munson Street  
CT, 06511  
United States

**WEBSITE**

[www.kleopharmaceuticals.com](http://www.kleopharmaceuticals.com)

**E-MAIL**

[stilman@tiberend.com](mailto:stilman@tiberend.com)

**PHONE**

+1 646 604 5149

**COMPANY TYPE**

Private

**SECTOR**

Pharmaceuticals/Licensing

**FOUNDED**

2015

## Kleo Pharmaceuticals, Inc.

### COMPANY PROFILE

Kleo Pharmaceuticals is a unique immuno-oncology company developing next-generation bispecific compounds designed to emulate or enhance the activity of biologics. Kleo's compounds directly engage patients' immune system to target and destroy cancer cells. Unlike biologics, Kleo's compounds are smaller and more versatile, leading to potentially improved safety and efficacy. They are faster and less costly to design and produce, particularly against novel targets. The company is advancing several drug candidates based on its proprietary technology platforms, each of which is modular in design enabling rapid generation of novel immunotherapies that can be optimized against cancer and other diseases or enhance the properties of existing biologics.

### MANAGEMENT TEAM

- Doug Manion M.D., Chief Executive Officer
- Luca Rastelli, Ph.D. Chief Scientific Officer
- Roy Prieb, Co-Founder, Chief Operating & Financial Officer

### PRODUCTS

Product #1

#### Antibody Recruiting Molecules (ARMs)

Antibody Recruiting Molecules (ARMs) are bispecific molecules that recruit endogenous antibodies to target cancer cells for immune destruction. They are comprised of two distinct binding domains connected by a tunable linker domain. One binding domain attaches to circulating antibodies and the other attaches to tumor cells.

Product #2

#### Synthetic Antibody Mimics (SyAMs)

Synthetic Antibody Mimics (SyAMs) are bispecific molecules that directly engage immune effector cells to destroy cancer cells. They're comprised of an optimized immune cell-binding domain linked to a highly specific tumor-binding domain.

Product #3

#### Monoclonal Antibody Therapy Enhancer (MATE)

Monoclonal Antibody Therapy Enhancers (MATEs) are synthetic compounds that are chemically conjugated with existing therapeutic monoclonal antibodies to enhance their ability to engage different components of the immune system. They are composed of an optimized immune cell-binding domain covalently bound to the antibody via a tunable linker domain.

**ADDRESS**

3200 Southwest Freeway  
Suite 2240  
Houston, 77027  
United States

**WEBSITE**

www.markertherapeutics.com

**E-MAIL**

investor.relations@markertherapeutics.com

**PHONE**

+1 713 400 6400

**COMPANY TYPE**

Public

**TICKER**

[NASDAQ: MRKR]

**SECTOR**

Biotechnology  
Pharmaceuticals/Licensing

**FOUNDED**

2018

## Marker Therapeutics, Inc.

### COMPANY PROFILE

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient's immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.

### MANAGEMENT TEAM

- Peter L. Hoang - President & CEO
- Anthony H. Kim - CFO
- Juan Vera, M.D. - Chief Development Officer
- Ann M. Leen, Ph.D - Chief Scientific Officer
- Michael J. Loiacono - Chief Accounting Officer
- Ken Moseley, J.D. - SVP & General Counsel
- Mythili Koneru, M.D., Ph.D - SVP of Clinical Development
- Gerald Garrett - VP of Clinical Operations
- Tsvetelina P. Hoang, Ph.D - VP of Research and Development
- Shelia Sterr - Director of HR and Finance

### FINANCIAL SUMMARY

Marker Therapeutics reported cash and cash equivalents totaling \$61.7 million as of December 31, 2018. Based on current operating plans, Marker expects that current cash resources will be sufficient to meet operating requirements into Q4 of 2020.

### PRODUCTS

Product #1

#### Multi Tumor-Associated Antigen (MultiTAA)

Marker's unique MultiTAA technology differs significantly from today's leading cell therapies. Marker's therapies have shown consistent evidence of "epitope spreading", requires no gene modification of T cells, and no cases of cytokine release syndrome of related serious adverse events.

Product #2

#### TPIV200

TPIV200 is a T cell vaccine that consists of five naturally processed peptide antigens derived from the highly prevalent tumor cell surface molecule, Folate Receptor Alpha. FR $\alpha$  is overexpressed by ~90% of ovarian cancer cells and 80% of triple-negative breast cancer cells, making it an ideal target for comprehensive immunotherapy.

Product #3  
**TPIV100/110**

The antigens that comprise TPIV110 were selected for binding to both MHC class I and class II. Because this vaccine utilizes multiple class II-restricted peptides, it can target a significant portion of the population unlike conventional class I-restricted single peptide vaccines.

**PIPELINE**









**ADDRESS**

100 avenue de Suffren  
Paris, 75015  
France

**WEBSITE**

www.ose-immuno.com

**E-MAIL**

contact@ose-immuno.com

**PHONE**

+33 153 198 757

**COMPANY TYPE**

Public

**TICKER**

[EPA: OSE]

**SECTOR**

Biotechnology

**FOUNDED**

2012

## OSE Immunotherapeutics

### COMPANY PROFILE

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company has a diversified first-in-class clinical portfolio consisting of several scientific and technological platforms including neoepitopes and agonist or antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases.

### MANAGEMENT TEAM

- Alexis Peyroles - CEO
- Dominique Costantini, M.D., Immunology - Director of Early Development
- Maryvonne Hiance - Director of Strategy
- Nicolas Poirier - CSO

### FINANCIAL SUMMARY

As of December 31, 2018: Turnover of €24,5 million Global profit of €5,5 million R&D expenses: - €15,1 million Overhead expenses: - €3,4 million Income tax: €0,8 million Cash available end of 2018 of €12,4 million (€9,6 M in cash & cash equivalents and €2,9 M in current financial assets) Expected cash-in S1 2019 Exercise of option 1 by Servier (OSE-127) : + €10 million HT BI milestone after CTA and dosing of first patient: + €15 million HT

### PIPELINE

## First-in-Class Portfolio Immuno-Oncology and Auto-Immune Diseases

PROGRAM	Indication	Humanized lead	Pre-Clinical POC	Phase 1	Phase 2	Phase 3	Partners
<b>IMMUNO-ONCOLOGY</b>							
Tedopi® Neoepitopes	NSCLC					EU-US-Isr Ongoing	
Tedopi®	Advanced pancreatic				Combo with PD1 Opdivo® Ongoing		GERCOR Bristol-Myers Squibb
BI 765063 + (OSE-172) SIRPα	Various cancers			Approvals received			Boehringer Ingelheim
OSE-703 + IL-7R	Various cancers		2019				Memorial Sloan Kettering Cancer Center
BiCKI® Bispecific anti-PD-1 & Innovative Targets	Various cancers		2019				
<b>AUTO-IMMUNE DISEASES</b>							
FR104 + CD28	Rheumatoid arthritis				2019		
OSE-127 + IL-7R	Ulcerative Colitis Sjögren syndrome			Ongoing			SERVIER



+ First-in-class product



**ADDRESS**

Windrush Court, Transport Way  
Oxford, OX4 6LT  
United Kingdom

**WEBSITE**

www.oxb.com

**E-MAIL**

enquires@oxb.com

**PHONE**

+44 1865 783 000

**COMPANY TYPE**

Public

**TICKER**

[LSE:OXB]

**SECTOR**

Biotechnology

**FOUNDED**

1996

## Oxford Biomedica Plc.

### COMPANY PROFILE

Using our unique LentiVector® delivery platform, we have created a valuable portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We have strong partnerships with Novartis, Sanofi Group, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations and Orchard Therapeutics, providing them with access to our intellectual property, state-of-the-art production facilities and expertise, and, in addition, we have licensed products and technology rights to Boehringer Ingelheim, Sanofi and Axovant. These partnerships provide us with multiple income streams, consisting of upfront milestone payments, development and production fees and potential royalties on future product sales. We plan to progress our wholly-owned products via spin-outs and out-licensing opportunities, while continuing to invest in our LentiVector® platform. We plan to continue our preclinical R&D to discover new potential products.

### MANAGEMENT TEAM

- John Dawson - Chief Executive Officer
- Stuart Paynter - Chief Financial Officer
- Jason Slingsby - Chief Business Officer
- Kyri Mitrophanous - Chief Scientific Officer
- Nick Page - Chief Operations Officer
- James Miskin - Chief Technical Officer
- Helen Stephenson-Ellis - Chief People Officer
- Lisa Giles - Chief Projects & Performance Officer
- Dmitry Zamoryakhin - Interim Chief Medical Officer

### FINANCIAL SUMMARY

For the year ended 31 December 2018, OXB reported:

- Revenue of £66.8 million
- Licence income of £18.3 million
- Cash at 31 December 2018 of £32.2 million

### PIPELINE

#### Oxford Biomedica proprietary products (to be spun-out or out-licensed)

<b>OXB-202</b>	Ophthalmology (corneal graft rejection)	Phase I/II trial preparation
<b>OXB-302</b>	Cancer (Multiple)	Pre-Clinical complete
<b>OXB-201</b>	Ophthalmology (Wet AMD)	Phase I complete
<b>OXB-204</b>	Ophthalmology (LCA10)	Pre-Clinical
<b>OXB-208</b>	Ophthalmology (RP1)	Pre-Clinical
<b>OXB-103</b>	CNS (ALS)	Pre-Clinical



**ADDRESS**

257 Simarano Drive, Suite 101  
Marlborough, 01752  
United States

**WEBSITE**

www.phioharma.com

**E-MAIL**

ir@phioharma.com

**PHONE**

+1 508 767 3861

**COMPANY TYPE**

Public

**TICKER**

[NASDAQ: PHIO]

**SECTOR**

Biotechnology  
Immuno-Oncology

**FOUNDED**

2012

## Phio Pharmaceuticals Corp.

### COMPANY PROFILE

Phio Pharmaceuticals Corp. is a biotechnology company developing the next generation of immuno-oncology therapeutics based on our self-delivering RNAi (“sd-rxRNA®”) therapeutic platform. The Company’s efforts are focused on developing sd-rxRNA therapeutic compounds to be used in the context of adoptive cell transfer by targeting checkpoints or other gene targets, or to be used in immunotherapy following intra-tumoral injections. We aim to maximize the power of our sd-rxRNA therapeutic compounds by weaponizing therapeutic immune effector cells to attack cancer, and to make tumors more susceptible to such attacks, and ultimately provide patients battling cancers with a powerful new treatment option that goes beyond current treatment modalities.

### MANAGEMENT TEAM

- Gerrit Dispersyn, Dr. Med. Sc. - President & CEO
- John A. Barrett, Ph.D. - Chief Development Officer
- James Cardia, Ph.D. - Vice President of Business Operations
- Caitlin Kontulis - Vice President of Finance & Administration

### PIPELINE

TREATMENT	INDICATION	DISCOVERY	PRE-IND	CLINICAL
Checkpoint Inhibition in ACT (TILs)	Melanoma	RXI-762		
Checkpoint Inhibition in ACT (TILs)	Ovarian Cancer	RXI-762		
Checkpoint Inhibition in ACT (TILs)	Head & Neck	RXI-762		
Checkpoint Inhibition in ACT (TCRs)	Other	RXI-762		
Checkpoint Inhibition in ACT (T-cells)	Various	RXI-804		
Checkpoint Inhibition in ACT (other)	Various	RXI-804		
Cell Maturation in ACT	Various	Undisclosed		
Cell Metabolism in ACT	Various	Undisclosed		
Direct Tumor / TME target	Melanoma	Undisclosed		
Direct Tumor / TME target	Various	Undisclosed		
Direct Tumor / TME target	Various	Undisclosed		





**ADDRESS**

1505 Adams Drive, Suite D  
Menlo Park, 94025  
United States

**WEBSITE**

www.refugebiotech.com

**E-MAIL**

Katherine@canalecomm.com

**PHONE**

+1 650 487 2650

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology

**FOUNDED**

2014

## Refuge Biotechnologies, Inc.

### COMPANY PROFILE

Refuge Biotech utilizes gene editing technologies, CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), to develop intelligent therapeutic cells that can make decisions inside the body. Contrary to CRISPR’s way of editing the DNA by cutting, Refuge is leveraging their proprietary receptor-dCas platform to create genetically programmable switches that have the ability to regulate multiple gene expressions. By turning the CRISPRi/a systems into an immuno-oncology tool, Refuge can treat a broad range of cancers, including lymphomas and solid tumor cancers, safer and more precisely than other immunotherapies. Refuge aims to change the current paradigm by combining different cancer treatment modalities into a single cell without damaging the DNA.

### MANAGEMENT TEAM

- Bing Wang, Ph.D., - Chief Executive Officer
- Jing Zhao - Chief Business Office
- Francesco Marincola, M.D., - Chief Scientific Officer
- “James” Jianbin Wang, Ph.D., - Director of Research, Gene Editing & Regulation
- Ida Louie - Senior Director of Finance and Operations
- Monique Dao, Ph.D., - Senior Director of IO Pre-Clinical Development

### FINANCIAL SUMMARY

Refuge is a discovery-stage therapeutic company focused on gene editing and genetic engineering of immune cells for cancer immunotherapy. The company has raised about \$34 million through a series A and series B financing rounds. Currently, Refuge has three programs in development to treat patients with lymphoma and various solid tumors, and they will be advancing their first clinical compound into clinic this year to prove its safety and tolerability.

### PIPELINE

Target	sgRNA	Indication(s)	Delivery	Discovery	Lead Optimization	Clinical
HER2	PD-1	Ovarian	Intratumoral	[Progress bar]		
	PD-1, TIM-3	GBM		[Progress bar]		
CD19	PD-1	NHL	Intravenous	[Progress bar]		
		B-ALL		[Progress bar]		
		CLL		[Progress bar]		
Undisclosed	PD-1, TIM-3, Undisclosed	AML	Intravenous	[Progress bar]		
		MDS		[Progress bar]		
Undisclosed	PD-1, TIM-3, Undisclosed	GBM	Intratumoral	[Progress bar]		
		Pancreatic Cancer		[Progress bar]		

**ADDRESS**

3000 Parmenter st.  
Middleton, 53562  
United States

**WEBSITE**

www.scinote.net

**E-MAIL**

klemen@scinote.net

**PHONE**

+1 386 1235 0520

**COMPANY TYPE**

Emerging

**SECTOR**

Academia  
Biotechnology  
CRO  
Diagnostics

**FOUNDED**

2016

## SciNote LLC

### COMPANY PROFILE


SciNote LLC develops reliable software solutions that connect and empower scientists. Its flagship product, SciNote, is a digital lab notebook that is currently among the top 5 software solutions of its type in the world. SciNote enables scientists to replace their paper notebook with a digital lab version and offers new possibilities for scientific data management and manuscript writing. It is also able to connect with lab instruments and other software solutions used in the labs, to provide users with a unique platform that enables data to be stored safely and shared among collaborators. Founded in 2016, the Company is a joint venture between Gilson Inc, one of the leading companies for automation instrumentation and chromatography systems, and BioSistemika LLC, one of the top software development companies for life science laboratories. SciNote LLC is led by CEO, Klemen Zupancic, PhD and headquartered in Middleton, WI with offices in Ljubljana, Slovenia.

### PRODUCTS

#### PRODUCT #1

##### SciNote

SciNote - Platform for Researchers SciNote is a top-rated platform for researchers in academia or industry, who need electronic lab notebook, inventory management and project management functionalities. It is being used by researchers at world's top-rated institutions, universities and companies.





**ADDRESS**

401 Professional Drive  
Suite 280  
Gaithersburg, MD 20879  
United States

**WEBSITE**

www.sirnaomics.net

**E-MAIL**

info-office@sirnaomics.com

**PHONE**

+1 301 740 1730

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology

**FOUNDED**

2007

## Sirnaomics, Inc.

### COMPANY PROFILE

Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs.

The key differentiating feature is the proprietary Polypeptide Nano-Particle (PNP) technology for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. The clinical development pipeline is focused on oncology and fibrosis indications.

Through the internal research and collaborations with prominent labs at NIH, Johns Hopkins, Duke, University of Maryland and Penn State, Sirnaomics has developed a strong portfolio of intellectual property covering RNAi therapeutic products, key biological mechanisms of action and unique PNP delivery system.

The management team collectively has extensive drug development experience, as well as specialized expertise in the areas of oligonucleotide therapeutics and nanoparticle-mediated delivery.

### MANAGEMENT TEAM

- Patrick Lu, Ph.D. - President & CEO
- Michael Molyneaux, M.D., MBA - Chief Medical Officer
- David Evans, Ph.D. - Chief Scientific Officer
- Dmitry Samarsky, Ph.D. - Chief Technology Officer
- Marc Lemaitre, Ph.D. - Chief Production Officer
- George Ji, MBA - Chief Operation Officer
- Nigel Yip - Vice President, Corporate Finance

### PIPELINE

TA	Name	Indication	API	Orphan	Commercial Right	R&D Studies	IND Enabling	IND Filing	Phase I Clinic	Phase II Clinic
Oncology	STP705	Non-Melanoma Skin Cancer (NMSC)	siRNA		Global	[Progress bar]				
	STP705L	Liver Cancer (CCA)	siRNA	*	Global	[Progress bar]				
	STP705L	Liver Cancer (HCC), I-O Study	siRNA	*	Global	[Progress bar]				
	STP705L	Pancreatic Cancer, I-O Study	siRNA	*	Global	[Progress bar]				
	STP302	Colorectal Cancer (CRC)	miRNA		Global	[Progress bar]				
	STP503	Glioblastoma Multiforme (GBM)	siRNA	*	Global	[Progress bar]				
	STP778	Head & Neck Cancer, Melanoma	siRNA		Global	[Progress bar]				
Anti-Fibrosis	STP705	Hypertrophic Scar Reduction	siRNA		Global	[Progress bar]				
	STP705L	Liver Fibrosis (PSC)	siRNA	*	Global	[Progress bar]				
	STP705L	Liver Fibrosis (NASH)	siRNA		Global	[Progress bar]				

\* Received Orphan Drug Designation      [Yellow bar] China Study

**ADDRESS**

400 E Randolph Suite 705  
Chicago, 60601  
United States

**WEBSITE**

www.siwatherapeutics.com

**E-MAIL**

msgruber@siwacorp.com

**PHONE**

+1 312 961 5109

**COMPANY TYPE**

Private

**SECTOR**

Diagnostics  
Pharmaceuticals/Licensing

**FOUNDED**

2006

## SIWA Therapeutics, Inc.

### COMPANY PROFILE

SIWA is a pre-clinical stage company. Our focus is on aggressive cancers, and we are completing requisite work to file an IND for an identified cancer within the next year. We have in vivo results showing that treatment with SIWA 318M, a mouse homolog of therapeutic candidate, SIWA 318H, statistically significantly: (1) inhibited cancer metastasis without increasing primary tumor growth in a 4T1 triple negative breast cancer model; and (2) consistent with the evidence that removal of SCs is a normal part of the regeneration process, it (a) restored muscle mass in normally aged mice back to a level comparable to young mouse controls; and (b) reduced SCs by two-thirds from the level of very old mice down to the level of young mouse controls. SCs are causally implicated in age-related dysfunction and in degenerative diseases including cancer. SCs act primarily by secreting substances which interfere with normal functions of other cells; thus, removing them should improve healthspan and lifespan. Our SIWA-identified advanced glycation end product ("AGE") target antigen is common to both senescent cells ("SCs") and cancer cells as both cell types have in common (a) an abnormally high level of glycolysis and (b) presence of our marker which is produced by glycolysis. Our mAb can thereby target both SCs and cancer cells for immune destruction. Because SCs in the tumor microenvironment feed, promote progression and suppress immune removal of cancer cells, SIWA 318H has a unique capability of killing cancer cells and eliminating the microenvironment which favors tumor initiation, progression and metastasis.

### MANAGEMENT TEAM

- Lewis S. Gruber, SIWA CEO, was interim CEO of a natural killer cell line product; company before founding SIWA. He was co-founder/ CEO of Arrayx, Inc. Arrayx, received awards including World Economic Forum Technology Pioneer
- Misty Gruber, SIWA CAO. was Co-Chair of the Dykema Gossett PLLC law firm's biotechnology section and focused on corporate finance.
- Thomas Tang, Ph.D., SIWA SAB, is a founder of First Dimension BioSciences has over 90 issued US patents.
- Nina McLain, Ph.D., SIWA SAB, is a University of Southern Mississippi professor. As Co-Principal Investigator, she has contributed to research resulting in pharmaceutical products.

### FINANCIAL SUMMARY

SIWA is completing a Series A round of financing to complete its pre-clinical work.

### PRODUCTS

Product #1

#### Humanized monoclonal antibody, SIWA 318H

Our lead product is a humanized mAb, SIWA 318H, that targets and binds to a SIWA-identified cell surface marker on both SCs and cancer cells for removed through normal immune surveillance. SIWA 318H is being tested in pre-clinical pharmacokinetic and toxicology work required for filing of an IND





**ADDRESS**

9433 Bee Caves Road  
Austin, 78733  
United States

**WEBSITE**

www.triumvira.com

**E-MAIL**

partners@triumvira.com

**PHONE**

+1 512 790 0222

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology  
Pharmaceuticals/Licensing

**FOUNDED**

2015

## Triumvira Immunologics, Inc.

### COMPANY PROFILE

Triumvira Immunologics is a biotechnology company developing a novel platform for engineering T cells to attack cancers. Our innovative and proprietary technology, called the T Cell-Antigen Coupler (or TAC), possesses advantages over other approaches because of the differentiated structure and biology of the TAC construct. In contrast to the Chimeric Antigen Receptor (CAR), the TAC receptor signals through the T cell receptor complex and thus leverages the endogenous activating and counter-regulatory pathways used by T cells normally during engagement with target cells. Thus the TAC provides a nuanced and regulated activation of the T cell. We believe this activity will translate to improved clinical safety and efficacy in both solid tumors and hematological malignancies, as we have seen evidence of this in preclinical models. Our lead program is entering the clinic in 1H19. Additionally, we are pursuing development of an allogeneic platform.

### MANAGEMENT TEAM

- Paul Lammers, MD, MSc, - President and Chief Executive Officer
- Jonathan Bramson, PhD. - Chief Scientific Officer
- Sabine Chlosta, MD, PhD. - Chief Medical Officer
- Donna Rill - Chief Technology Officer
- Andreas Bader, PhD - Senior Vice President, R&D
- Joshua Carle - Vice President, Business Development
- Jon Irvin - Vice President, Finance
- Cynthia Molina - Vice President, Regulatory Affairs

### FINANCIAL SUMMARY

Privately Held, currently raising Series A

### PIPELINE

## Pipeline of Transformational Candidates



PROGRAM	DISCOVERY	PRECLINICAL	IND-ENABLING	PHASE I/II
TAC01-CD19	CD19+ B-cell malignancies (NHL, leukemias)			Start H1 – 2019
TAC01-HER2	HER2+ solid tumors (GBM, breast, gastric)			Start H2 – 2019
TAC02-BCMA (allogeneic)	Multiple Myeloma			Start H1 – 2020
TAC01-ROR1	ROR1+ solid tumors (lung, breast, colon)			Start H2 – 2020
Undisclosed Targets (2)	Indications TBD			Start 2021
Allogeneic ("off the Shelf")	e.g., γδ- or iNKT-cells			
Enhancements	Next Generation TAC T cells			
Combinations	TAC + Other Therapies			

### Technology Platform with:

- Multiple Product Candidates
- Liquid & Solid Tumor Targets
- Autologous & Allogeneic cells
- Multi-Targeting
- Opportunity with combinations

**ADDRESS**

Av Generalitat 152-158  
Sant Cugat del Valles  
Barcelona, 08174  
Spain

**WEBSITE**

[www.vcnbiosciences.com](http://www.vcnbiosciences.com)

**E-MAIL**

[mcascallo@vcnbiosciences.com](mailto:mcascallo@vcnbiosciences.com)

**PHONE**

+34 935 712 359

**COMPANY TYPE**

Private

**SECTOR**

Biotechnology  
Pharmaceuticals/Licensing

**FOUNDED**

2009

## VCN Biosciences SL

### COMPANY PROFILE

VCN Biosciences is a clinical-stage company focused on the immuno-oncology space harnessing the power of oncolytic viruses. Our next generation oncolytic adenoviruses are designed to obtain clinical activity by systemic administration and remodel complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and immune system. Our scientists have developed a flexible technological platform with a solid IP position (4 exclusive patent families) and our candidates are currently tested in different clinical trials showing their mechanism of action and activity.

### MANAGEMENT TEAM

- Manel Cascalló, PhD – CEO
- Carmen Blasco, PhD – Clinical Operations Manager
- Miriam Bazan Peregrino, PhD (Oxon) – R&D Manager
- Ernest Milián, PhD – CMC Manager
- Emma Blasi – Regulatory Affairs Manager

### PRODUCTS

Product #1

#### VCN-01

VCN-01 is an oncolytic adenovirus virus genetically modified to allow efficient systemic delivery. It also expresses hyaluronidase (a tumor matrix degrading enzyme) facilitating therapeutics entry (chemotherapy; antibodies) and the immune system into tumor. It's currently being tested in 4 independent clinical trials where it has already demonstrated its activity

Product #2

#### VCN-11

VCN-11 is a next generation oncolytic adenovirus expressing hyaluronidase (facilitating the entry of therapeutics and the immune system into tumors) which also includes a capsid modification to prevent binding of neutralizing antibodies. These properties confers VCN-11 a unique systemic targeting profile in pre-immunized models together with an excellent safety profile.



**ADDRESS**  
500 Mercer Street  
Seattle, 98109  
United States

**WEBSITE**  
www.rainierrx.com

**E-MAIL**  
jeastland@rainierrx.com

**PHONE**  
+1 206 7180 223

**COMPANY TYPE**  
Private

**SECTOR**  
Biotechnology

**FOUNDED**  
2012

## Rainier Therapeutics, Inc.

### COMPANY PROFILE

Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of both early stage and metastatic bladder cancer, areas of high unmet need. Our lead program is a human monoclonal antibody, known as vofatamab, that targets and specifically blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist known in development.

### MANAGEMENT TEAM

- Scott Myers - Chairman and Chief Executive Officer
- Dr. Steve Abella - Chief Medical Officer
- Dr. Graeme Currie - Chief Operating Officer
- Julie Eastland - Chief Business Officer and Chief Financial Officer
- Gary Christianson - Chief Technology Officer

### PIPELINE

## Vofatamab Development Program Poised to Move into Pivotal Trial

Clinical Trial	Phase 1	Phase 2	Phase 3 / Pivotal	Patient Status	Setting	Next Anticipated Milestone
<b>Advanced and Metastatic Bladder Cancer</b>						
Fierce-22	Combination with pembro (N=up to 92 pts)			All Patients	Post-platinum	Interim data: 2019
Fierce-21	Combination with chemotherapy (N=20 pts)			Mutant/ Gene Fusion	Post-platinum and CPI*	Interim data: 2H 2019
	Monotherapy (N=20 pts)			Mutant/ Gene Fusion	Post-platinum and CPI*	Interim data: 2H 2019
<b>Non-Muscle Invasive Bladder Cancer</b>						
Fierce-23	Monotherapy and Combination with CPI ** (N=100 pts)			All Patients	BCG unresponsive	Trial initiation: Pending

\* CPI=Checkpoint inhibitor  
\*\* Planned initiation in 2019

As of May 2019. Anticipated milestones are best estimates and are subject to change and update



**SILVER SPONSOR****BeiGene****BeiGene Ltd.**[www.beigene.com](http://www.beigene.com)

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,100 employees in China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.



## SUPPORTERS



### **BioPartner**

[www.biopartner.co.uk](http://www.biopartner.co.uk)

BioPartner is an independent, government-accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartner Programme, members receive extra benefits and support to effectively trade overseas.



### **Biotechgate**

[www.biotechgate.com](http://www.biotechgate.com)

Biotechgate is a global, comprehensive, life science database covering the Biotech, Pharma and Medtech industries. There are currently over 36,000 company profiles on the Biotechgate database. Biotechgate is commonly used to find product pipelines, collaboration partners, in/out-licensing opportunities and information about technology platforms, management details, new business leads and financing rounds. In addition, our licensing deals database supports companies in negotiating their licensing agreements.



### **Citigate Dewe Rogerson**

[www.citigatedr.co.uk](http://www.citigatedr.co.uk)

Citigate Dewe Rogerson is one of the world's leading strategic communications consultancies.

Our Life Sciences team has established a reputation for excellence spanning financial, corporate and scientific communications; this has enabled us to become trusted advisors and to build a broad portfolio including some of the most innovative and exciting international life sciences companies. Our clients are at all stages of development, from start-up to multinationals, and our activities are focused on delivering campaigns that support corporate objectives. As a result, we have been involved in major corporate transactions and events in the life sciences sector over the past decade such as IPOs, other public and private fundraisings, and M&As.

Recent IPO transactions: ABIVAX (Euronext Paris - €60m), OSE Pharma (Euronext Paris - €21m), Nordic Nanovector (Oslo - NOK575m), Midatech Pharma (London AIM - £32m), Abzena (London AIM - £20m), arGEN-X (Brussels - €42m), Pixium Vision (Euronext Paris - €39.5m), Crossject (Euronext Paris - €17m). Other recent financings: Abingworth (£225m ABV VI), Rigontec (€14.25m Series A), Calcivis (£4.5m fundraising), ViraTherapeutics (\$3.6m - Series A). Recent M&A: Heptares (up to \$400m acquisition by Sosei), Prosonix (up to £100m acquisition by Circasia), bioquell (Sale of subsidiary for £44.5m).



## Edison Group

[www.edisongroup.com](http://www.edisongroup.com)

Edison is an international advisory firm with around 450 corporate clients and 110 people working from offices in London, New York, Frankfurt, Sydney and Wellington. The team consists of 80 analysts, investment and logistics professionals with experience in capital markets, investor roadshows and communications. Health-care is Edison's largest sector, with 16 analysts covering over 100 biotech and med-tech stocks across the UK, continental Europe, North America and Asia-Pacific.



## FreeMind

[www.freemindconsultants.com](http://www.freemindconsultants.com)

FreeMind is a consulting group whose goal is to assist in maximizing potential to receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind working with academics and Industry alike. FreeMind's proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations.

FreeMind's knowledgeable and experienced team of Client Strategists and Project Managers are dedicated to guiding non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. Our team of experts will assist in making non-dilutive funding a key tool in a long-term financial strategy.



## Instinctif Partners

[www.lifesciences.instinctif.com](http://www.lifesciences.instinctif.com)

Instinctif Partners is an international business communications consultancy. With a track record of delivering truly creative programmes, the Life Sciences practice focuses on enhancing the value proposition for companies seeking investment, partnerships or customers. Our core skill is working with clients to communicate the value of their science and innovation to key stakeholders through the most relevant channels: crafting communications solutions that showcase each company, product or technology. Specifically, we are unique in offering specialist expertise seamlessly across corporate, financial, healthcare and marketing communications with outreach programmes to media, industry, professional, public, financial and investment communities. Our service offering covers all communications disciplines including strategic counsel, PR, IR, media relations, public affairs, crisis communications, internal communications, marketing, advertising, copywriting, design, research and event management. Our globally integrated and dedicated life sciences team serves clients around the world from our headquarters in London, and bases across Europe, AsiaPac and the USA.



## Ontario Bioscience Innovation Organization

[www.obio.ca](http://www.obio.ca)

The Ontario Bioscience Innovation Organization (OBIO®) founded in 2009, is a not-for-profit, membership based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario's human health science companies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, patients and government.



## Plattform Life Sciences

[www.goingpublic.de/lifesciences](http://www.goingpublic.de/lifesciences)

The Life Sciences-Series - Launched in 2014 four issues of the Life Sciences-Series appear annually. Based on the three pillars – technology, financing, investment – the issues combine current topics of life sciences with knowledge and networking from corporate financing and capital market. The mission: Building a cross medial bridge between the life sciences and the financial industry by the help of the quarterly Life Sciences issues, the monthly digital newsletter LifeSciencesUpdate



## SwissBiotech

[www.swissbiotech.org](http://www.swissbiotech.org)

The Swiss Biotech Association represents the interests of the biotech sector, supports the entrepreneurship of biotech companies, and generates value for them through the following activities:

- Development of optimal framework conditions for the biotech sector:
- Networking of stakeholders at national and international level:
- Dissemination of accomplishments in biotechnology:
- Collaboration with strategic partners



## Tiberend Strategic Advisors, Inc.

[www.tiberendstrategicadvisors.com](http://www.tiberendstrategicadvisors.com)

Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies:

1. To enhance valuation
2. To build visibility for partnerships and strategic alliances

## **SACHS ASSOCIATES**

[www.sachsforum.com](http://www.sachsforum.com)

Sachs Associates is a long established international conference company with offices in Switzerland and the UK. It runs a limited number of high profile conferences in Europe and the USA which are focused on biopharma, medtech, and digital health. These conferences focus on licensing and investment opportunities and all provide presenting opportunities for companies and excellent meeting facilities for all delegates to network.

Sachs Associates is focused on the practical benefits accruing from conference participation, the exchange of ideas and information, and the facilitating of business transactions.

## **THE BENEFITS OF CONFERENCE PARTICIPATION WITH SACHS ASSOCIATES MAY BE SUMMARISED AS FOLLOWS:**

### **ONLINE ONE-2-ONE MEETING SYSTEM**

In order to offer the best possible provision for networking opportunities and deal making Sachs Associates provides all delegates access to our online One-2-One meeting system, allowing you to set up, accept or decline private One-2-One meetings with other conference attendees. These meetings last for 20 minutes in duration. Individual passwords and logins are provided to allow immediate access and ensure full security.

### **CUTTING EDGE CONTENT WITH EMINENT SPEAKERS**

Sachs Associates is committed to ensuring that its events continue to provide forums with the participation of the most eminent speakers from the public and private sectors. Through its reputation and its long-established local relationships, the company has attracted very senior scientific and business personalities as speakers at its events.

### **SPONSORSHIP AND MARKETING OPPORTUNITIES FOR FORTHCOMING EVENTS**

Sachs Associates has developed an extensive knowledge of the key individuals operating within the global biotech industry. This together with a growing reputation for excellence puts Sachs Associates at the forefront of the industry and provides a powerful tool by which to increase your company position in this market. Sponsorship of any of our events allows you to raise your company's profile directly with your potential clients. All of our sponsorship packages are tailor-made to each client, allowing your organisation to gain the most out of attending our industry driven events.

## **THE FOLLOWING SPONSORSHIP AND MARKETING OPPORTUNITIES ARE AVAILABLE AT FUTURE CONFERENCES:**

- Conference Sponsor - including workshops and social events
- Exhibition Stands
- Distribution of Promotional Material

If your company is interested in exhibiting or sponsorship opportunities, please call Silvia Kar on +44 203 463 4890 or email [Silvia@sachsforum.com](mailto:Silvia@sachsforum.com).





**SACHS**  
**ASSOCIATES**

[WWW.SACHSFORUM.COM](http://WWW.SACHSFORUM.COM)